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1. SKELETAL SYSTEM 
 
 
1.1 BONE STRUCTURE 
 
Bone is a dynamic, vascular, living tissue that changes throughout life, is one of the so-called 
“connective tissues” of the body and thus comprises cells that become embedded in their own 
extracellular matrix. Bone is highly specialized with a complex, hierarchical structure over multiple 
levels (Standring S, 2008). Given bone tissue’s ability to adapt its mass and morphology to 
functional demands, its ability to repair itself without leaving a scar, and its capacity to rapidly 
mobilize mineral stores on metabolic demand, bone is considered the ultimate “smart” material 
and a dynamic example of “form follows function” in biological systems. The principal role of the 
bone is to provide structural support for the body and while the bone also serves as the body’s 
mineral reservoir and producer of blood cells, the mineralized structure is the very basis of 
posture, opposes muscular contraction resulting in motion, withstands functional load bearing, 
and protects internal organs (Kneser U, et al., 2006).  
It is composed of an extracellular matrix (ECM) which has been represented as a two-phases 
composite, characterized by an organic phase (35%) composed by 90% of collagenous proteins 
(97% collagen I and 3% collagen III, IV and V) and 10% of non collagenous proteins (mainly 
osteocalcin, osteonectin, sialoproteins, proteoglycans, osteopontin, fibronectin, Growth Factors 
and bone morphogenetic proteins), reinforced with inorganic (65%) component, characterized by 
calcium phosphate hydroxyapatite [(Ca10(PO4)6(OH)2)] crystals (HA, TCP) with a Ca:P ratio of 5:3, 
sodium (Na), magnesium (Mg) and potassium (K) (Figure 1). Apatite crystals are nanoscale, 
elongate, plate-like and orientated in relation to the direction of primary stress (Amizuka N, 2004). 
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Fig. 1. Bone extracellular matrix (ECM) composition. 
 
Bone growth factors (GFs) and cytokines influence the synthesis and resorption of bone by acting 
on the local cell population present in bone marrow and on bone. They are local regulators of cell 
growth, function and angiogenesis. Bone matrix contains a great number of GFs and cytokines 
such as, Interleukin I , VI and IX (IL-I, VI, IX), Tumor necrosis factor α (TNF-α),  Transforming growth 
factor beta supergene family (TGF-β1-5 and Bone Morphogenetic Proteins-BMPs), Platelet-derived 
growth factors (PDGFs), insulin-like growth factor I and II (IGF-I and-II), fibroblast growth factors 
(FGFs), as indicated in Table 1 (Soheim E, 1998).  
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Tab. 1. Cytokine and GF functions and sources in bone. 
 
CYTOKINES 
AND GFs 
BONE 
FORMATION 
BONE 
RESORPTION 
POTENTIAL SOURCES IN BONE 
IL-I + +++ Osteoblasts 
IL-VI ? +/- Osteoblasts 
IL-IX ++ ++ Osteoblasts 
TNF-α + +++ Osteoblasts 
TGF-β and 
BMPs 
++ ++ Osteoblasts, bone matrix 
PDGFs ++ ++ Platelets, osteoblasts, bone matrix 
IGF-I +++  Osteoblasts, bone matrix 
IGF-II +++  Osteoblasts, bone matrix 
FGFs +++  Osteoblasts, bone matrix 
 
Histologically (Figure 2), bone is identified as lamellar bone, consisting of lamellae (3-7 μm in 
thickness) composed of bone matrix and osteocytes each occupating a cavity (lacuna). Canaliculi 
penetrate the lamellae of adjacent lacunae. The osteon or  Haversian system is formed by 
arranged lamellae around a longitudinal vascular channel. The osteons are parallel to one another 
in skeletrical districts where tension forces prevail. Vascular anastomosis are present between 
vascular channels of adjacent osteons, as branches that run perpendicular to Haversian channels 
(Volkmann channels) (Laz PJ, et al., 2007). 
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Fig.2. Bone structure. (Image from http://training.seer.cancer.gov/anatomy/skeletal/tissue.html). 
 
Bone tissue is arranged in two macroarchitectural forms-cortical (or compact) and cancellous (or 
trabecular, or spongy)- which are employed in various proportions and geometries to form the 
individual bones of the body (Figure 3). The latter can be broadly subdivided into four groups: long 
bones (femur, tibia, fibula, humerus, radius, and ulna); short bones such as those of the carpus 
(wrist) and tarsus (ankle); flat bones such as those of the calvaria (skull vault); and irregular bones 
(the remaining bones of the skull, the scapula, and pelvic bones).  
In cortical bone, densely packed collagen fibrils form concentric lamellae, and the fibrils in 
adjacent lamellae run in perpendicular planes as in plywood, whereas, cancellous bone has a 
loosely organized, porous matrix. Cortical bone is almost solid with less than 10% of porosity, in 
contrast, cancellous bone is organized in a porous sponge-like pattern. Cortical bone has loading 
fibers orientated along the loading axis with highly organized structures such as the Haversian 
system. Cancellous bone has a cortex of cortical tissue consisting of longitudinally oriented 
osteons that are typically of the order of 200 µm in diameter and 10-20 mm in length.  The cortical 
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has greater apparent modulus of elasticity, tensile strength, and fracture toughness than 
cancellous bone. However, owing to the highly porous structure (cancellous bone 75-90%; cortical 
bone 5-10%), relative properties of the ECM are similar (Davies JE, 2003). In general, strength of 
bone depends on the hardness of the compact cortical bone and on the underlying scaffolding 
effect of the trabeculae of cancellous bone. 
The cortical bone has evolved to withstand torsional loading, while the function of cancellous 
bone is to withstand predominantly compressive loading.  
About 3-5 % of one’s skeleton is being eaten away by osteoclasts and replaced by osteoblasts, 
throughout life from six weeks in utero, when bone first forms, until we die. This constant 
remodeling of bone tissue provides a mechanism for scar-free healing and regeneration of 
damaged bone tissue, and results in the exquisite lamellar microarchitecture of both cortical and 
trabecular mature bone. 
From this perspective,  therefore, trabecular bone represents a biologically superior tissue, ideally 
evolved for rapid bone healing, when compared to the slowly remodeling healing pattern typical 
of cortical bone. On the other hand, cancellous bone is finer and more delicate in appearance. Its 
physical arrangement of broad plates, connected by thin struts, provides for maximum support 
but with a minimum of raw material. The metabolic activity of cancellous bone is thought to be 
considerably higher than that of cortical bone, with the result that diseases, which are caused by 
aberrations of metabolism, are invariably seen in the cancellous compartment first. 
Cancellous bone has a very high surface area, which is contiguous with the marrow compartment. 
Since marrow contains not only mesenchymal progenitor cells, that can give rise to osteoblasts, 
but also a rich vasculature that can supply both the circulating mononuclear precursors to 
osteoclasts (needed for remodeling) and the endothelial population needed for angiogenesis, it is 
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not surprising that trabecular bone can remodel more quickly than cortical bone (Henriksen K, et 
al., 2009). 
 
Fig.3. Bone structure. a) Cancellous and b) cortical bone. Toluidine blue, fast green staining. Magnification 10x. (Image 
from Laboratory of Preclinical and Surgical Studies-IOR).  
 
The entire surface of bone, except where articular cartilage is present, is covered by specialized 
dense connective tissue known as periosteum. This layer is attached to the cortical bone below by 
a series of collagenous bundles known as Sharpey fibers and the strength of these attachments 
varies between different bones. The internal surface of bone, which includes the medullary cavity, 
cavities of the haversian system of compact bones and the trabeculae of cancellous bone, is lined 
with another connective layer, endosteum (Hing KA, 2004). 
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1.2 BONE CELLS 
Bone is composed of four different cell types: osteoblasts, osteocytes, osteoclasts and 
osteoprogenitor cells. 
 
1.2.1 Osteoblasts 
Osteoblasts (Figure 4) are epithelial-like cells that are fully differentiated and polarized cells (20-
30µm of diameter) within bone and derived by the differentiation of osteoprogenitor cells.  
 
Fig.4. Osteoblasts. Scanning electron Microscopy (SEM). Magnification 1950x. (Image from laboratory of Preclinical 
and Surgical Studies-IOR). 
 
They have a spherical or ovoid nucleus, lay down the extracellular matrix and regulate 
mineralization, depositing osteoid, nonmineralized organic matrix and initiating the subsequent 
mineralization of the osteoid. They secrete the type I Collagen and the non collagenous proteins of 
the bone matrix such as osteocalcin, osteopontin, bone sialoproteins and GFs such as BMPs. 
Morphologically, they are cuboidal or columnar in shape and located at the bone surface together 
with their precursors, where they form a tight layer of cells. The lifespan of an osteoblast ranges 
between 3 days in young rabbits up to 8 weeks in humans, during which time it lays down 0.5-1.5 
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µm osteoid per day. Eventually, some osteoblasts may become trapped in their own calcified 
matrix, changing their phenotype and developing into osteocytes. In fact, when bone formation is 
completed, osteoblasts flatten out and transform into osteocytes (Henriksen K, et al., 2009).  
                
1.2.2 Osteocytes 
Osteocytes (Figure 5) are the most abundant resident cells (>90%) in bone tissue. They are 
regularly spaced in lacunae throughout the calcified bone matrix and communicate with each 
other as well as with the cells on bone surface, osteoblasts and osteoprogenitor cells, through a 
large number of cytoplasmic processes running in bone canaliculi. Osteocytes are no longer 
involved in bone formation. Due to their inaccessibility and difficulty in cell culture, osteocytes 
have not received enough attention and little is known about their function for a long time. 
However, in recent years, these mysterious cells shed new light on their pivotal function in 
regulation of new bone formation and remodeling (Huang CP, et al., 2008; Takai E, et al., 2004). 
The large population, ideal location and unique morphologies make osteocytes ideal candidates 
for detection of external stimulations and generation of signals that affect osteoblasts, osteoclasts 
and their progenitors in the bone marrow. An analogy might be made between the bone cells 
network and neuronal system. 
Osteocytes may play the role as the ‘‘brain center’’, and their principal function is thought to be in 
intercellular signaling by the extensive cellular network (Huang CP, et al., 2008). 
Osteocytes form extensive interconnected 3D cellular networks that position them to be suitable 
sensors of changes in the local mechanical and hormonal environment in bone tissue. 
Mechanical stimuli such as hydrostatic pressure, fluid shear, and load-induced strain have been 
shown to elicit a response from osteocytes both in vitro and in vivo. Unlike other in vitro 
applications of mechanical stimuli such as membrane stretch, which can induce concomitant fluid 
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flow-induced effects (e.g., shear stress, streaming potentials, nutrient convection), and fluid shear 
stress, which is driven by a pressure gradient, hydrostatic pressure can be applied uniformly to all 
cells without other modes of mechanical stimulation (Warden SJ, 2006). 
Osteocytes are not capable of division and are lost when the bone in which they reside is 
degraded, so the osteocyte’s lifespan is dictated by the lifespan of the bone and they can remain 
alive for years provided vascularization is continuous.  
                             
 
 Fig.5. Osteocytes in lacunae. Scanning electron Microscopy (SEM). Magnification 1950x. (Image from laboratory of 
Preclinical and Surgical Studies-IOR). 
 
1.2.3 Osteoclasts 
Osteoclasts (Figure 6) are large (from 20 to 100µm in diameter), highly migratory and 
multinucleated cells that resorb bone and when active, they rest directly on the bone surface and 
have two plasma membrane specializations. They are highly polarized cells that occupy the 
Howship’s lacuna.  
The main feature of osteoclasts is their ability to resorb fully mineralized bone at Howship’s 
lacunae. Both macrophages and osteoclasts are derived from hematopoietic stem cells (monocyte-
macrophage progenitor cell lineage) and, similar to macrophages, they carry an arsenal of 
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lysosomal enzymes. A resorption bay is formed underneath the cell into which the lytic enzymes 
are secreted. In addition, proton pumps lower the pH in this subosteoclastic space to values 
between 2 and 4, activating the secreted enzymes such as tartrate-resistant acid phosphatase. 
Osteoclasts are transiently active in response to a metabolic demand for the mobilization of 
calcium from bone into blood. An activated osteoclast, with an average lifespan of 15-20 days, is 
able to resorb 200,00 µm3/day, an amount of bone formed by seven to ten generations of 
osteoblasts (Standring S, 2008).  
    
Fig.6. Osteoclast. Scanning electron Microscopy (SEM). Magnification 1950x. (Image from laboratory of Preclinical and 
Surgical Studies-IOR). 
 
1.2.4 Osteoprogenitor cells 
The regenerative potential of our body depends on specialized stem cells, characterized by their 
functions to differentiate into different cell lineages and to self-renew for the maintenance of the 
stem cell pool. Since the late 19th century, bone marrow (BM) has been known to host 
mesenchymal stem cells (MSCs), also called osteoprogenitor cells or bone-lining cells, which are 
able to differentiate into multiple mesodermal tissues such as bone, cartilage, adipose, muscle, 
tendon, stroma, and neuronal cells (Figure 7).  
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These cells have a direct role in the maintenance of bone balance. They act as a source of 
progenitors for osteoblasts and moreover, constitutively secrete a distinct set of cytokines, sug-
gesting that they serve specific supportive functions in the microenvironment of BM. MSCs are the 
cells competent for bone tissue maintenance and regeneration: their self-renewal and differen-
tiating properties in an osteogenic lineage make them very useful tools in tissue engineering and 
regenerative medicine. Osteoprogenitor cells differentiation toward a specific lineage is 
dependent on hormonal and local factors, commonly called the microenvironment (e.g., leptin, 
cell-cell-signaling, extracellular matrix, and cytokines), which can activate specific transcription 
factors. Although it has been reported their use as a part of bone grafting procedures, that have a 
clinical potential, many clinical variables (e.g., the anatomic site of BM harvest, recent trauma, 
local or systemic bone diseases, menopausal status, use of tobacco or pharmaceutical agents, age 
and gender) might contribute to differences in MSC samples.  
Fig. 7.  Osteoprogenitor cells. Scanning electron Microscopy (SEM). Magnification 1950x. (Image from laboratory of Preclinical 
and Surgical Studies-IOR). 
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Osteoprogenitor cells persist throughout postnatal life as bone-lining cells and they are 
reactivated in the adult, during the repair of bone fractures and other injuries (Veronesi F, et al., 
2011).  
 
1.3 BONE MODELING AND REMODELING 
Already in 1892, Wolff found that the orientation of trabeculae coincides with the direction of the 
stress trajectories. He proposed that bone loading is somehow sensed and that the bone adapts its 
structure accordingly. This principle of functional adaptation is generally known as “Wolff’s Law” 
(Wolff J, 1892). The ability of bone to adapt to mechanical loads is brought about by continuous 
bone resorption and bone formation. If these processes occur at different locations, the bone 
morphology is altered. Frost defined this as modeling (Frost HM, 2001).  
In a homeostatic equilibrium, resorption and formation are balanced and, in that case, old bone is 
continuously replaced by new tissue. This ensures that the mechanical integrity of the bone is 
maintained but it causes no global changes in morphology. Frost defined this as remodeling (Frost 
HM, 2001). The modeling and remodeling processes are not very different at the cellular level. 
They are based on the separate actions of bone resorbing cells (osteoclasts) and bone forming 
cells (osteoblasts). Approximately 10% of the skeleton is renewed each year by remodeling. This 
process is necessary to repair skeletal microfractures, to prevent accumulation of older and 
weaker bone, and to maintain mineral homeostasis (Fini M, et al., 2010).  
This process is complex and characterized by the coordinated actions of osteoclasts and 
osteoblasts, organized in basic multicellular units (BMU) that follow a cycle of  resorption, reversal, 
formation, and resting phases (Figure 8). Remodeling begins with the migration of partially 
differentiated mononuclear pre-osteoclasts to the bone surface where they form multinucleated 
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osteoclasts. The signal that initiates the resorption phase is thought to be the mechanical stress 
that alters local bone architecture and is sensed and transduced by osteocytes. After osteoclastic 
resorption, which takes about 3 weeks, there is a reversal phase when mononuclear cells on the 
bone surface provide signals for osteoblast differentiation and migration and this phase lasts up to 
4-5 weeks. In the formation phase, osteoblasts lay down bone until the resorbed bone is 
completely replaced by new bone; this phase may last for about 3 months. Eventually, bone 
surface is covered with flattened lining cells and a resting period follows. This dynamic process 
occurs in BMUs at multiple sites simultaneously throughout the skeleton (Gallagher CJ, 2008). 
 
Fig.8. Bone remodeling cycle in healthy conditions. (Image fromhttp://www.ns.umich.edu). 
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1.4 BONE HEALING  
A fracture or a bone defect means that the continuity of a bone is disrupted. During the course of 
healing, different types of tissues can be seen in a lesion area, whereby one substitutes the other 
(Figure 9).  
The striking feature of bone healing, compared to healing in other tissues, is that repair doesn’t 
create a scar tissue. This is linked to the capacity for remodeling which intact bone possesses.  
The healing of bone fracture and defect has traditionally been described in four phases. 
1) Haematoma formation (inflammation or granulation) phase 
 
Initially, a hematoma is found between the fragment ends. The hematoma might well act as a 
guiding structure which, as a spacer, determines the size and shape of the callus. 
Activated platelets release a variety of products, including fibronectin, PDGF and TGF-β, which 
trigger the influx of inflammatory cells. The subsequent cytokine cascade brings the cells of repair 
(fibroblasts, endothelial cells and osteoblasts) into the fracture gap. 
2) Soft callus formation (proliferative) phase. 
This is characterised by the formation of connective tissues, including cartilage, and formation of 
new capillaries from pre-existing vessels (angiogenesis). In detail, during the first few days the 
hematoma changes to become granulation tissue. Capillary sprouts, mononuclear cells, 
fibroblasts, and fibrocytes are present. During the process of healing, a maturation of this 
granulation tissue is observed and it is transformed into connective tissue with its collagen fibers. 
This maturation results in an increase in stiffness. 
3) Hard callus formation (maturing or modeling) phase. 
This phase leads to woven bone, either directly from mesenchymal tissue (intramembranous) or 
via an intermediate stage of cartilage (endochondral or chondroid routes). Osteoblasts can form 
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woven bone rapidly, but it is randomly arranged and mechanically weak. During this step, in both 
fibrous tissue and fibrocartilage, mineralization occurs.  
4) Remodeling phase. 
Woven bone is remodeled into stronger lamellar bone by the orchestrated action of osteoclast 
bone resorption and osteoblast bone formation. In this phase the mineralization is followed by 
local resorption of the mineralized cartilage, whereby new vessels enter the fracture area. The 
walls of the resorption spaces are then covered with lamellar bone, thus forming new bone 
trabeculae. A further bone deposition, combined with local resorption, leads to a reshaping of 
those trabeculae (Marsh DR and Li G, 1999).  
Thus, a gradual increase in strength and stiffness occurs, along with a reduction of the ability to 
elongate (Dimitriou R, et al., 2005; Gerstenfeld LC, et al., 2003).  
In terms of extracellular matrix formation, type III collagen predominates at the inflammatory 
stage, followed by type II collagen in the cartilaginous phase and type I collagen production at the 
ossification and remodeling stages. 
 
Fig.9. Steps of the bone healing process. (Image from http://apbrwww5.apsu.edu). 
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Bone regeneration is a highly efficient and tightly regulated process that involves all the above-
mentioned components of bone tissue. Bone regeneration is the result of a continuous interplay 
between GFs and cytokines for both initiation and regulation of the remodeling process. The 
majority of fractures heals well under standard conservative or surgical therapy. However, 
extended bone defects, following trauma or cancer resection or non-unions of fractures, may 
require more sophisticated treatments. In these cases bone grafting procedures, segmental bone 
transport, distraction osteogenesis or biomaterials are applied for reconstruction (Kneser U, et al., 
2006). 
 
1.4.1 Bone healing complications  
Bone tissue, usually, has the ability to repair itself, but when complicated fractures and large bone 
defects have to be bridged, the healing process fails in many cases. Despite the advent of modern 
techniques, individual fractures occasionally refuse to heal and a non-union or pseudoarthrosis 
can occur.  Insufficient blood supply and infections of the callus or the surrounding tissue or even 
systemic diseases can have further negative effects on bone regeneration, resulting in the 
formation of a non-union (Janicki P and Schmidmaier G, 2011). 
The healing process may be classified into 4 separate entities: union, malunion, non-union, and 
pseudoarthrosis. Union is used to described a fracture that has united; in malunion the fracture 
has united but the union is incorrectly aligned; non-union occurs when the apposed ends of the 
fracture have failed to unite and to ossify. The amount of healing, that has occurred, may vary 
from a cartilaginous bridge, which has failed to ossify, to fibrous-connective tissue, or to an 
absolute lack of bridging. Non-unions can also occur after the bone resection caused by cysts, 
benignant and malignant tumors and by congenital malformations and osteomyelitis (Sumner-
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Smith G, 2002). Pseudoarthrosis indicates a true false-joint formation when bone needs are joined 
by a fibrous joint-capsule-like structure, which contains synovial-like fluid originating from local 
serum production.   
Nearly 5-10% of all fractures is associated with impaired healing, resulting in delayed union or 
non-union.  
Bone defects are very challenging in orthopaedic practice; they can result from a high-energy 
traumatic event, from large bone resection for different pathologies such as tumor or infection, or 
from the treatment of complex non-unions (en-bloc resection). They can be considered critical in 
relation to the skeletal segment involved and the length of bone loss: 3 cm for the forearm, 5 cm 
in the femur and tibia, 6 cm in the humerus (Janicki P and Schmidmaier G, 2011). 
The main clinical pathologies that could require a graft or a biomaterial implantation are, as well 
as the above mentioned non-unions and pseudoarthrosis, the bone fractures with loss of 
substance. For these defects, there is a constant demand for substitutes which can effectively 
bridge long segmental defect or fill loss of substances with minimal morbidity and accelerating 
healing times. Tissue regeneration has become a great challenge for many illness, traumatic 
lesions or reconstructive needs (Fini M, et al., 2005).  
The amount of repair, however, depends on the size of the bone defect, the lesion site and the 
patient’s health status, the age and lifestyle. For critical size defects (would not fully heal 
spontaneously) and for the above mentioned defects, or even to accelerate or geode the repair 
process, the use of bioactive scaffolding materials could be of great advantage. The use of bone-
filling materials with the properties of adsorption, osteopromotion, safety and ease of sterilizing, 
manufacture and surgical use may improve the healing rate, making the difference between 
success and failure (Yamada Y, et al., 2003).  
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Nevertheless, it is still a great challenge in reconstructive surgery to treat large bone defects or 
non-unions. The therapy concept, based on bone substitutes, includes the possibility to rebuild 
bone lacking structure and to allow migration, proliferation and differentiation of bone cells and to 
promote vascularisation (Nandi SK, et al., 2010). 
Approximately 2.2 million bone graft procedures are performed each year worldwide to repair 
bone defects in orthopaedics, neurosurgery and oral and maxillofacial surgery with a yearly 
estimated costs of $ 2.5 billion.  
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2. BONE GRAFTS 
A tissue graft is a medical procedure in which tissue from a donor is used to replace missing or 
damaged tissue on a patient. Numerous types of human tissue can be used including veins, skin, 
tendons, bone, and ocular materials. In general, tissue grafting can be divided into 3 major 
categories according to the genetic relationship between the donor and the recipient. They are a) 
autogenous tissue graft (autograft): a tissue graft from one site to another within the same 
individual; b) allogenous tissue graft (allograft): a tissue graft between individuals of the same 
species; d) xenogenous tissue graft (xenograft): donor and recipient are individuals from different 
species (Delloye C, et al., 2003).  
In orthopaedic field, regarding bone healing, bone grafts can be osteogenic, osteoinductive and 
osteoconductive. 
A graft that supplies and supports bone forming cells is termed osteogenic. 
Osteoinductive agents (proteins) induce proliferation or differentiation of undifferentiated stem 
cells to osteogenic cells. A graft that has the capacity to induce bone formation when placed into a 
site where no bone formation will occur is termed osteoinductive. Osteoconduction is the process 
whereby scaffolding is provided for inward migration of cellular elements involved in bone 
formation (mesenchymal cells, osteoblasts, osteoclasts and vasculature) (Kneser U, et al., 2006).  
Autogenous bone graft is the transplantation of bone taken from one anatomic site to another 
site in the same individual. It is defined as the 'gold standard' for regeneration, is a safe solution 
for compatibility and the absence of immune response, and it is considered to be the most 
suitable material, because the graft has osteogenic (marrow-derived osteoblastic cells as well as 
preosteoblastic precursor cells), osteoinductive (noncollagenous bone matrix proteins, including 
GFs) and osteoconductive properties (bone mineral and collagen) (Kneser U, et al., 2006). 
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Moreover, the differences in histocompatibility and the risk of transferring a disease are not 
existent. On the other hand, the autograft drawbacks include: an insufficient amount of graft 
material necessary to replace the missing portion, particularly in children or in bone loss due to 
tumors; a significant postsurgical morbidity at the donor site; increased surgical time and blood 
loss and an additional cost due to a possible prolongation of the hospitalization. The different 
types of autogenous bone grafts are represented by autologous cancellous bone, autologous 
cortical bone and vascularized autografts. Autologous cancellous bone plays a dominant role in 
bone-transplant surgery because osteogenic stem cells can survive in an autogenic spongiosa and 
it has a clinical success in the treatment of a wide range of diseases, such as delayed fracture 
healing, pseudoarthrosis, bone defects and infections. It has a robust biological activity in inducing 
and producing new bone (Sen MK and Miclau T, 2007). It has been considered more osteogenic as 
compared to cortical bone graft because the presence of spaces within its structure, allowing the 
diffusion of nutrients and limited revascularization, but it does not provide substantial structural 
support. The principle advantage of autologous cancellous grafts is the potential to transfer 
osteoprogenitor cells combined with matrix and signals, provided by the cancellous particles, 
yielding a mixture that contains other factors of bone regenerative strategy.  
Another example of an osteogenic material is bone marrow. Bone marrow aspirates contain MSC, 
cells already committed to osteogenic or chondrogenic lineage, and some biologically active 
proteins that stimulate bone regeneration in similar manner to naturally occurring fracture clot, 
many from platelet degranulation. However, use of bone marrow does not yield the magnitude of 
osteogenesis observed with cancellous bone for several reasons. Aspiration results in varying 
quality of bone marrow depending on technique and patient. Osteoprogenitor cell content can be 
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low and most importantly, bone marrow lacks the necessary scaffold or osteoconductive material 
to be efficacious on its own (Kolk A, et al., 2012). 
Autologous cortical bone graft has little or no osteoinductive properties, is mostly 
osteoconductive, and the surviving osteoblasts provide some osteogenic properties as well. It is 
much less important, for bone regeneration, than cancellous bone due to its poor vascularity and 
its low content of osteogenic stem cells. Thus, the only role for free cortical autografts in bone 
regeneration is the temporary increase in mechanical stability (Beaman FD, et al., 2006). 
Autologous cortical bone grafts are good choices for segmental defects of bone of 5 to 6 cm, 
which require immediate structural support.  
Vascularized cortical autograft heals rapidly at the host-graft-interface, and its remodeling is 
similar to that of normal bone. It improves osteocyte survival and enhances bony incorporation. It 
appears to demonstrate less bony necrosis with no subsequent trabecular collapse and no 
architectural disorganization, when compared with the non-vascularized grafts (Kawamura K, et 
al., 2008).  
The limitation associated with the procurement of autograft for bone grafting and the 
development of modern tissue banks have resulted in a supply of high-quality allogenic tissue for 
reconstructive orthopaedic surgery. Allograft overcomes the limitations associated with the 
procurement of autografts for bone grafting. It may be derived from cadaveric bone sources or 
from living donors harvested during hip arthroplasty, and has both osteoinductive (they release 
bone morphogenic proteins that act on bone cells) and osteoconductive properties, but it lacks 
osteogenic properties because of the absence of viable cells. Beside limitations in the essential 
bone graft characteristics, there is an ongoing controversial discussion about the association of 
allogenic material with a risk of transmission of infectious agents such as the human 
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immunodeficiency virus (HIV), hepatitis B and C viral infection (HBV/HCV), malignancies, systemic 
disorders (autoimmune disease), or toxins. Removal of osteoarthritic femoral heads throughout 
hip arthroplasty shows an 8% evidence of diseases not previously known. Elimination of this major 
concern of allogenic material requires tissue-processing, sterilization and a deactivation process of 
proteins in the extracellular matrix which contains bone growth factors, proteins, and other 
bioactive substances necessary for osteoinduction and, ultimately, successful bone healing. 
Although the risk of transmission of disease is much lower than with blood products, it is still 
possible. The more aggressive the allograft processing, the less intense immunologic responses 
will occur, but this results in a decrease of the osteoinductive properties. For this reason fresh 
allografts are clinically no longer used. Frozen allografts induce stronger immune responses than 
freeze-dried allografts (Habibovic P and de Groot K, 2007).  
Compared with autologous cancellous bone, allograft cancellous bone is a poor promoter of bone 
healing. Allogenic cortical bone incorporation occurs by sporadic formation of new appositional 
bone and the lack of vascularization leads to weakness of the graft. It is used in replacing segments 
of bone after tumor excision, in lengthening bones and in treating selected non-unions.  
Massive osteochondral allografts (diaphyseal cortical bone, metaphyseal cancellous bone and 
articular cartilage) are used in joint reconstruction after limb salvage procedures for tumor 
resection and in traumatic bone loss. Some complications are represented by allograft fracture, 
articular cartilage degeneration, osteoarthritis, deep infections and non-unions.  
Xenograft is a tissue graft between two different species and despite its wide availability, the 
untreated xenogenic bone is an unsuitable transplant material because it provokes a strong 
immunodefensive reactions. Porous natural hydroxyapatite (HA) can be obtained from animal 
bones or seaweeds. Xenogenic HA is the preferred biological material because of its stability 
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concerning absorption (i.e. dependent on the porosity value, crystallinity, crystal structure, etc.) 
(Kolk A, et al., 2012). 
In the last few years, Demineralized Bone Matrix (DBM) has attracted attention as bone graft. 
DBM consists of sponge-like collagen from human, bovine or equine origin that has undergone 
decalcification and sterilization, so it can be classified as allogenic or xenogenic material 
dependent on the origin. The trabecular structure of the original tissue remains, therefore 
maintaining its biological structure. DBM has been shown to have osteoconductive and 
osteoinductive properties, but it provides no structural stability and therefore should only be 
applied in a structurally stable environment (Naujoks C, et al., 2011). 
It is mainly used as a ‘‘bone graft extender’’, revascularizes quickly and acts as suitable carrier for 
autologous bone marrow, it does not evoke any appreciable local foreign body reaction as the 
antigenic surface structure of the bone is destroyed during demineralization. More growth factors 
are available after the removal of bone minerals, so the bone inductance of DBM is higher than 
that associated with mineralized allogenic transplants. DBM is a derivative of allograft bone and it 
could be prepared by pulverization of allogenic bone to a consistent size, followed by mild acid 
extraction of the mineralized phase of bone. This process, principally developed by Urist et al in 
1965, results in a composite of non-collagenous proteins, growth factors, and collagen (Urist MR 
and Dawson E, 1981). 
Nowadays, bone graft materials with completely different origins are commercially available for 
many applications throughout the human body. They are variable in their composition, their 
mechanism of action and, therefore, their indications. In conclusion, problems related to the 
availability of graft material, donor-site morbidity, immunogenicity and biomechanical integrity 
represent some limitations of bone grafts and clinical success. 
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Bone substitute materials are generally considered to be a highly important alternative to bone 
grafting.  
Due to the numerous disadvantages present in all kinds of grafts, there is a rationale for the 
designing and developing of artificial supports (scaffolds) for tissue engineering applications and 
their demand is growing steadily. The alternative to tissue grafting is the use of artificial designed 
scaffolds or implants, fabricated using various materials (biomaterials). Nowadays, materials, 
including metals, polymers, ceramics and composites, are used clinically for implants and medical 
devices in many medical areas (Yan Y et al., 2009).  
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3. BIOMATERIALS 
The term “Biomaterial” can be defined as “a material intended to interface with biological systems 
to evaluate, treat, augment or replace any tissue, organ or function of the body”. This is still a 
good conceptual definition, but should be modified to take into account the extended applications 
of biomaterials. Moreover, the variety and complexity of these applications is such that a 
classification of biomaterials might be considered. A slightly modified definition of biomaterial is 
proposed as follows: “ a material intended to interface with biological systems as an integral part 
of a process designed to evaluate, monitor or treat tissues of the body, to replace or augment 
tissues or to facilitate the regeneration of tissues” (ESB satellite Consensus Conference, Sorrento, 
September 2005).  
Current requirements for an ideal biomaterial as bone substitute are rigorous as listed below: 
- Resorbability/degradability and sterility 
- Biocompatibility 
- Osteoinduction, osteoconduction, osseointegration 
 
Resorption of the material and replacement by normal bone are either biologically based on the 
influence of cells or by chemical-physical dissolving processes, and should occur simultaneously in 
the ideal case. The biomaterial should be easy to use, should withstand sterilization and should 
come in sufficient quantities. In a time of global economic downturns, costs are an important issue 
in clinical applications (Kao ST and Scott DD, 2007).  
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3.1 BIOCOMPATIBILITY 
Biocompatibility ensures the absence of toxicity, teratogenicity or carcinogenicity. The lack of 
antigenicity guarantees the avoidance of pro-inflammatory and immunogenic reactions. All such 
requirements serve as a basis for effective long-term tolerance and such criteria are mainly 
fulfilled by available synthetic materials (Williams DF, 2008).  
Biocompatibility is a fundamental requirement of biomaterials and is defined as “the ability of a 
material to perform with an appropriate host response in a specific application” (Williams DF, 
1987). It is the essential requisite for the employment of a material in the biomedical field, is 
strictly related to the specific application and location of the biomedical device and can be defined 
as its substantial property of not alter the physiologic environment and not cause pathological 
outcomes. Since at the present time no absolutely inert materials exist, so it is probably more 
correct to describe biocompatibility as biotolerability. In 1995 Wintermantel and Mayer modified 
the definition of biocompatibility into surface and structural compatibility of implants, involving 
appropriate chemical, biological and physical characteristics, including surface morphology (for cell 
anchorage and guidance) (Wintermantel E and Mayer J, 1995). 
The assessment of biocompatibility is a mandatory prerequisite for all materials and devices 
before their clinical application. The evaluation of the biocompatibility of a material, assigned to 
clinical use, is a long trial that requires a well planned sequence of steps. The assessment of 
biocompatibility of a particular biomaterial entails the consecutive execution of well accepted 
scientific evaluations. Considered together, the results of these evaluations help to provide an 
objective picture of the associated composite biocompatibility and in general, the sequence of 
evaluations increases in complexity and scope over time, from basic in vitro cell culture 
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cytotoxicity evaluation to in vivo large animal anatomically relevant evaluations of biocompatibility 
and biofunctionality.  
These procedures are now standardized at an international level, in particular in the European 
Community, the rules of EN ISO 10993 provide the guide-lines for each investigation in this field. 
The International Organization for Standardization (ISO) is a worldwide federation of national 
standards bodies for the biological evaluation of medical devices. ISO 10993 refers to the 
fundamental principles governing the biological evaluation of medical devices, the definition of 
categories of devices based on the nature and duration of the contact with the body, and the 
selection of appropriate tests to be performed. Biocompatibility tests must be performed on the 
final product or material, taking into account the type, duration and conditions of the exposure in 
the human body, the physical and chemical features of the product, the toxicological activity of 
the chemical elements or compounds and the presence of leachable materials. It is not required 
that a material or device will be submitted to all the tests, but only to those related to the specific 
contact with the body environment (Gatti AM and Knowles JC, 2002). 
The capability of a biomaterial to perform  a specific function cannot be evaluated by single in vitro 
or single in vivo methodology. In vitro methods provide necessary and useful results that precede 
and complete the in vivo testing. In vitro tests decrease the number of animals required for in vivo 
biocompatibility evaluation, while in vivo evaluations allow long-term investigations, by 
reproducing the complex biological environment and are suitable for the evaluation of 
biofunctionality.  
A research project that adopts only an in vitro or an in vivo method is considered limited and a 
study conducted only in vitro is acceptable as a first step and becomes ethically unacceptable if 
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performed only in vivo with no preliminary in vitro information on the biomaterial biocompatibility 
(Fini M and Giardino R, 2003).  
In vitro cell cultures. The in vitro evaluation provides the initial biocompatibility screening and it is 
represented by target cell assays, making use of the most sensitive cells pertinent to the 
application for which the biomaterial is developed. Table.2 shows the benefits and limits of in vitro 
studies and some relevant negative aspects of the in vitro screening are represented by the 
minimization of the variables of metabolism, distribution, and adsorption, and the maximization of 
the cell line exposure to any potential toxicity. Moreover, there is difficulty to extrapolate the 
results to the clinical population. Consequently, an in vivo evaluation must be conducted.  
The impossibility of predicting, in vitro, the effect of biological fluids on biomaterials, which is 
responsible for the side-effects, as well as long-term prosthetic device behaviour, represents a real 
drawback of cell culture systems. On the other hand in vitro tests provide detailed information on 
particulate debris toxicity when identified.   
Osteosarcoma and immortalized cell lines are used, as well as primary cells from several species 
and anatomical locations. If human-derived primary cells are employed, they usually come from 
the surgical residues obtained during surgery (i.e. bone fragments unusable for tissue banking). 
Human osteosarcoma cell lines show the absence of individual variability observed when primary 
lines are used, as well as better repeatability and reproducibility.   
In vitro test sensitivity, in discriminating between safe and toxic biomaterials, is of great 
importance in rejecting inappropriate materials prior to the in vivo implantation. It is recognized 
that in vitro tests can be limited due to their relative simplicity when compared to the complex 
interactions occurring in an organism in toto, because of the lack of systemic and local factors due 
to the complexity of cell and tissue response (Negrou G, et al., 2008).  
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In vivo animal models. Animal models provide important biomaterial knowledge that leads to the 
development of more effective clinical treatments of diseases in both humans and animals, acting 
as a bridge between in vitro studies and clinical trials. Depending on the purpose of the study, 
biomaterials are usually implanted in the diaphyseal (cortical bone and medullar cavity), 
metaphyseal or epiphyseal part of long bones (cancellous bone). Common bone implant tests are 
histologic, histomorphometric and biomechanical investigations that can provide a complete 
characterization of the osteogenic and osteointegration properties of the material. Performing in 
vivo studies requires, first of all, compliance to ethical and legal rules on animal experimentation. 
Every Country has its own regulations, but a regional local ethical committee exists to approve 
every research protocol. Biomedical research, using animals, is regulated worldwide by precise 
rules. In the United States, the Animal Welfare Act dated from 1966 and this was followed in 1986 
by the Public Health Service Policy on Care and Use of Laboratory Animals. All of these documents 
contain guidelines about the animal environmental, housing and management as well as 
veterinary care. In the European Union, the Directive 86/609_Protection of Experimental Animals 
gives, to the state members of the European Community, indications to be applied in the 
regulation of animal research. According to this directive, the Italian Government, with the Law by 
decree number 116 of January 27,1992 on the protection of animals used for scientific purpose, 
settles the guidelines for this matter. Considering the biological evaluation of medical devices, part 
2 of ISO 10993 “Animal Welfare Requirements” contains the directives to be followed when 
animal tests are to be performed (Andersson M, et al., 2007; Andersson M, et al., 2008). 
The tests are justified only when the resulting data are not otherwise available and essential for 
the material characterization, when no other scientifically validated method not involving animals 
is available, and when strategies to minimize pain, suffering, distress and lasting harm have been 
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identified and implemented. Animal tests must be carried out in authorized laboratories, with 
appropriate facilities for animal stabling and welfare and must not be conducted before 
appropriate preliminary in vitro tests have been carried out with favorable results. Surgical 
procedures must be performed in general anaesthesia and in well equipped operatory rooms, 
under the control and responsibility of well trained scientists. In vivo tests for biocompatibility may 
use the biomaterials themselves or may utilize extracts of them to determine the toxicity and 
bioactivity of potential leachable, dissolution products, or other materials utilized in the synthesis 
and production of the biomaterial. Important limits of an in vivo study (Table 2) include the 
presence of differences that are so great between humans and animals, data on animal bone 
remodeling and formation that cannot be representative of bone healing in humans, the need for 
appropriate facilities and complex professional expertise, prolonged time and high costs (Buma P, 
et al., 2004). 
 
Tab.2. Benefits and limits of in vitro and in vivo studies.  
 
 BENEFITS LIMITS 
IN VITRO STUDIES 
High sensitivity; Standard 
experimental conditions; Human 
cells and tissues; No ethical 
drawbacks; Easy to perform, 
manage, interpret; Fast and 
inexpensive screening; Reduction of 
animal use and suffering. 
Specific sensitivity; Deposition of 
metabolic and toxic products (in 
static cultures); Partial information 
on biofunctionality and mechanical 
osteointegration; Lack of systemic 
factors; Difficulty in long-term 
studies. 
IN VIVO STUDIES 
Long-term investigations; 
Biofunctionality and effectiveness of 
the final prosthetic device; Presence 
of systemic factors; Biological 
environment. 
Ethical drawbacks; Legal 
authorization requirements; 
Appropriate facilities; Complex 
professional expertise; Prolonged 
time, high costs; Differences 
between humans and animals. 
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3.2 OSTEOINDUCTION, OSTEOCONDUCTION AND OSSEOINTEGRATION 
Osteoinduction is the ability to actively stimulate or promote bone formation. Osteoinductive 
biomaterials provide a biological stimulus for induction, recruitment, stimulation and 
differentiation of primitive, undifferentiated and pluripotent stromal cells into osteoblasts or 
preosteoblasts, the initial cellular phase of a bone-forming lineage (Calori GM, et al., 2011).  
Osteoconduction is defined as the process of bony ingrowth from local osseous tissue onto 
surfaces. Osteoconductivity is a property of the biomaterial that allows the colonization and 
ingrowth of new bone cells and sprouting capillaries due to its three-dimensional structure. The 
original definition is not strictly restricted to biomaterials, however, the contemporary concept of 
an osteoconductive material is one where bone formation is promoted to appose and conform to 
its surface, when the material is placed into bone, by virtue of its composition, shape or surface 
texture. Osteoconduction is mainly determined by the porosity properties of the biomaterials and 
also, in a lesser extent, by the chemical and physical properties of the substrate that promote cell 
adhesion and growth. Osteoconductivity is, by definition, a passive process (LeGeros RZ, 2002). 
For some biomaterials and dependent on implantation site, osseointegration is the process of 
achieving stable direct anchorage and contact between bone and biomaterials and it was firstly 
described by Branemark in 1977 and defined by Albrektsson in 1981 (Branemark PI, et al., 1977; 
Albrektsson T, et al., 1981). At an histological level it is defined as the direct anchorage of  a 
biomaterial by formation of bony tissue around the implant without the growth of fibrous tissue at 
the bone-implant interface. A biomechanical definition has also evolved stating that 
osseointegration is “a process whereby clinically asymptomatic rigid fixation of alloplastic 
materials is achieved and maintained, in bone, during functional loading” (Zarb G and Albrektsson 
T, 1991).  
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Osteoinduction, osteoconduction and osseointegration are powerful inter-related phenomena in 
bone regeneration and intrinsically related to bone morphogenetic proteins, bone growth factors 
and direct bone anchorage factors, respectively.  
To date, no bone substitute biomaterial is available that is equal to autogenous bone, and current 
biomaterials serve primarily as filling and frame building materials, mostly providing 
osteoconductivity for the bone healing process.  
Ideally, the healing process of the bone defects should result in regenerated and vital bone, 
without foreign bodies (Horch HH, et al., 2006).  
To reach this aim, tissue engineering applications are developed. 
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4. TISSUE ENGINEERING  
During the 1st Tissue Engineering  Symposium (California 1988), tissue engineering was defined, for 
the first time, as “application of the principles and methods of engineering and life sciences 
towards the fundamental and pathological mammalian tissues and the development of biological 
substitutes that restore, maintain or improve tissue function”(Fox CF and Skalak R, 1988). It was 
considered the point that best marked the transition to a new era of research. This large area 
confronts and engages different sciences such as engineering, chemistry, physics, biology, 
biotechnology and medicine in a multi-disciplinary approach for the development of functional 
tissues and organs in vitro, for their implantation in vivo or for direct remodeling and regeneration 
of tissue in vivo to repair, replace, preserve or enhance tissue or organ functions lost due to 
disease, injury or aging (Ingber DE, et.al,2006). 
The new therapeutic strategy consists in the use of tissue-engineered living cells (and / or their 
products) and innovative supports, to develop bioactive tissue substitutes as an alternative to 
inert systems and it is clear that the complexity of biological tissues in terms of macromolecular 
composition, organization and ultrastructural interactions between cells and the environment, 
makes it difficult the passage of engineered constructs from the experimental field to the clinic. 
Tissue engineering offers the potential to eliminate re-operation and to solve implant rejection, 
transmission of diseases and shortage in organ donations by using biological substitutes, providing 
long term solutions in tissue repair or treatment of diseases, and offering treatments for medical 
conditions that are untreatable (McIntire LV, 2003). So, aided by advances in biological and 
medical sciences, materials science and engineering, tissue engineering has triumphed in recent 
decades by providing various implant biomaterials for human tissue repair for millions of patients 
all over the world. The design and fabrication of scaffolds, with required properties, are key 
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components for tissue engineering. Tissue engineering typically uses artificial extracellular matrix, 
named scaffolds, to engineer new tissues. Scaffolds are tissue engineered product biomaterials 
defined as degradable materials used, through implantation or injection, in a host for the purpose 
of stimulating tissue engineering or cell therapy process. A porous structure, usually polymeric, 
serves as substrate and guide for tissue regeneration. Usually the terms scaffold and matrix are 
used interchangeably in this aspect (ESB satellite Consensus Conference, Sorrento, September 
2005).  
Tissue engineering proposes different alternative routes for all tissue repair and the bone scaffold 
based most important methodologies are the in vitro tissue engineering and the in situ tissue 
regeneration.  
The first involves the preparation of an in vitro engineered tissue, where autologous 
osteoprogenitor cells and signaling molecules  are ex vivo seeded and differentiated onto a 
scaffold; engineered constructs as well, once re-implanted into the patient, should be gradually 
resorbed and replaced by viable tissue with vascular and nervous contribution (Figure 10). In this 
way the tissue is regenerated outside the human body (Thompson MS , et al., 2010).  
 
Fig.10. In vitro tissue engineering with the use of scaffolds, autologous cells and signaling molecules. 
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The advantage of this methodology is the transplantation of a prefabricated functional tissue that  
releases cells and osteogenic factors, is incorporated and revascularized in the host body and 
starts the remodeling process. The disadvantages are represented by the law requirements, high 
costs and times of the different techniques for the fabrication of these constructs.  
The second approach (Figure 11), also called in vivo regeneration, is characterized by the in vivo 
implant of biological factors or scaffolds (with or without signaling molecules) in order to stimulate 
tissue regeneration. It is characterized by an acellular scaffold implantation, that stimulates the 
extracellular matrix and recruits or maintains, in the lesion site, cells and biological factors also 
from other body seats (Wan AC and Ying JY, 2010). 
 
 
 
Fig.11. In situ tissue regeneration is modeled as if it takes place inside a bioreactor which is surrounded by a reservoir. 
Exudate, that contains cells, cytokines and several other substances but not matrix components, flows continuously 
from the reservoir to the bioreactor. In in situ tissue regeneration the bioreactor is the living body and the reservoir 
the biological environment typical of a wound healing. 
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In situ tissue engineering requires the use of bioactive scaffolds. 
Bioactivity is a very widely used term. The definition, agreed at the second ESB Consensus 
Conference, Sorrento 2005, is as follows: “Phenomenon by which a biomaterial elicits or 
modulates biological activity”. However, there could be some forms of classification of bioactivity 
that reflect the nature of the modulation of biological activity. In vitro bone bioactivity is the up-
regulation of calcium phosphate deposition on a scaffold surface. In vivo bone bioactivity is the up-
regulation of the process of bone formation on the surface of a scaffold (ESB Consensus 
Conference, Sorrento 2005). 
Bioactivity is a phenomenon through which, a scaffold stimulates or modulates a biological 
response and creates an interaction between scaffold and living body through the activation of a 
specific physiological process (Ohtsuki C, et al., 2009).    
 
4.1 SCAFFOLDS 
Currently, scaffolds can be divided into two categories: natural and synthetic.  
Natural materials. Natural polymer-based materials consist of structural and functional proteins 
(such as collagens), proteoglycans, glycoproteins, and glycosaminoglycans found in a natural 
tissue, and they have been implanted for constructive remodeling of many tissues in preclinical 
and human clinical trials (Table 3). They are formed in nature during the growth cycles of all 
organisms, hence they are also referred to as biopolymers. Advantages of biopolymers over 
synthetics are their excellent physiological activities such as a selective adhesion and a similar 
mechanical properties to natural tissues, moreover, they have excellent biological properties, 
including cell adhesion, biodegradability and biocompatibility. The natural polymers mimic the 
decellularized native extracellular matrix down to the molecular level because many of them 
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possess the property of self-assembly, and are better materials for the biological system to 
recognize. They are degraded into noninflammatory products (a significant advantage over their 
synthetic counterparts), but their exact composition is often difficult to ascertain and reproduce 
and may be immunogenic because they carry a risk of microbiological contamination. Their 
relatively poor mechanical properties, undefined rate of degradation and propensity to induce an 
inflammatory response limit their range of applications (Fini M, 2005). 
 
Tab.3. Natural materials. Biocompatibility, disadvantages and applications. 
 
POLYMERS BIOCOMPATIBILITY DISADVANTAGES APPLICATIONS 
Collagen 
Minimal cytotoxicity, 
Mild foreign body 
reaction, Minimal 
inflammation 
Proteolytic removal of 
small nonhelical 
telopepties 
Skin; cartilage; bone; 
ligament; tendons; 
vessels; nerves; bladder; 
liver 
Hyaluronic acid 
Mild foreign body 
reaction, No 
inflammation 
Highly viscous solution, 
Many purification steps 
after chemical 
modification 
Skin; cartilage; bone; 
ligament; vessels; 
nerves; liver 
Alginic acid 
Minimal foreign body 
reaction, No 
inflammation 
Uncontrollable 
dissolution of hydrogel 
Skin; cartilage; bone; 
nerves; muscle; 
pancreas 
Chitosan 
Minimal foreign body 
reaction, No 
inflammation 
Uncontrollable 
deacetylation and 
molecular weight 
Skin; cartilage; bone; 
nerves; vessels; liver; 
pancreas 
Gelatin 
Minimal cytotoxicity, 
Mild foreign body 
reaction, Minimal 
inflammation 
Weak mechanical 
property 
Skin; cartilage; bone; 
ligaments; breast 
Fibrin 
Minimal cytotoxicity, 
Mild foreign body 
reaction, Minimal 
inflammation 
Weak mechanical 
property 
Skin; bone; cartilage; 
liver; tendons; ligament; 
vessels 
Poly(hydroxyalkanoate) 
Minimal cytotoxicity, 
Mild foreign body 
reaction, Minimal 
inflammation 
Pyrogen removed 
Skin; bone; tendons; 
cartilage; nerves; 
ligaments; heart; 
vessels; muscle 
Silk 
Minimal cytotoxicity, 
Mild foreign body 
reaction, Minimal 
inflammation 
Inflammation of sericin 
Skin; ligaments; bone; 
cartilage; tympanic 
membrane; vessels; 
tendons 
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Collagen based scaffolds have been used for bone tissue engineering, in fact, type I collagen is a 
major component of bone and leads to new bone from stem/progenitor cells via the 
developmental cascade. Therefore, type I collagen might be a good candidate material for a 
biomimetic approach to design artificial scaffolds for bone tissue engineering (Kim BS, et al., 2011).               
Another example of natural-based scaffolds is represented by the silk fibroin hydrogel that, in a 
Fini M et al. study, was comparatively investigated in terms of osteoblast function and healing of 
confined critical size cancellous bone defects. In vitro results on osteoblasts, showed the absence 
of inflammatory effects and a stimulation of TGF-β1 production. In vivo, it permitted the healing of 
critical size defects in the trabecular bone and silk fibroin hydrogel improved bone remodeling and 
maturation greatly. Therefore, it is considered potentially useful as bone replacement material in 
reconstructive orthopaedic surgery, being a readily available injectable biomaterial able to 
improve bone healing and maturation (Fini M, et al., 2005).  
Synthetic materials. These materials are attractive because they can be fabricated into various 
shapes and phases with desired pore morphologic features for tissue in-growth, and have the 
ability to tailor mechanical properties and degradation kinetics to suit various applications in 
repair and reconstruction of diseased and damaged parts of the human body. In orthopaedic, they 
provide mechanical support during tissue growth, can incorporate cells and growth factors and 
provide osteoconductive environments.  
The synthetic materials are usually classified in non-polymeric (metals and ceramics), polymeric 
and composites materials and are spreadly used in many human districts (Gunatillake PA and 
Adhikari R, 2003).  
Non-polymeric materials, including metallic and ceramic materials, have been used for bone tissue 
engineering. Metals are used in implant fabrication mainly because of their excellent mechanical 
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properties and the extensive knowledge-base of mankind with regard to their processing, 
properties and structures. They generally possess higher strength, ductility and water resistance, 
and they are used as passive substitutes and as supports for hard tissue repair or replacement in 
load-bearing applications such as total hip and knee joint replacements, for fracture healing aids 
such as bone plates, screws and wires, spinal fixation devices and for dental implants. Stainless 
steel and titanium or titanium alloys are the materials that usually comprise the basis of metal 
implants for bone regeneration (Wang W, et al., 2011). Generally, the mechanical properties of 
metallic materials are superior to those of polymeric ones. However, there are several 
disadvantages, such as the lack of tissue adherence, low rate of degradation, toxicity due to 
accumulation of metal ions due to corrosion, and mismatch of Young’s modulus between metallic 
materials and bone.  
The thermal and chemical stability of ceramics, high strength, wear resistance and durability, all 
contribute to make ceramics good candidate scaffolds for surgical implants. Bioceramics, 
especially calcium phosphates and HA, are preferred materials as bone grafts because of their 
excellent chemical stability, low density and compositional similarities with bone mineral phase. 
High strength bioceramics, such as aluminia and zirconia are also used for load-bearing 
applications, but like metals, these ceramics are “bioinert” and could form non-adherent fibrous 
capsule in vivo, leading to loosening of implants. Bioactive ceramics (such as HA) interact with the 
surrounding tissues and form strong interfacial bonds. They are composed of ions commonly 
found in physiological environments, which make them highly biocompatible, moreover they are 
resistant to microbial attack, pH changes and are stable during temperature changes. On the other 
hand, these ceramics exhibit poor mechanical strength and low crack growth resistance, which 
limit their uses to non-load-bearing applications (Zhou H and Lee J, 2011). Calcium phosphate can 
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be used in permanent implants or as biodegradable artificial scaffolds due to its osteoconductive 
and osteoinductive properties as well as mechanical compatibility with native bone.  
Tissue engineering has provided an alternative medical therapy using implants of polymeric 
scaffolds, with or without living precursor cells, as opposed to various transplants. Different 
polymers can be used as scaffolds to promote cell adhesion and maintenance of differentiated cell 
functions without hindering proliferation, in fact compared to metallic and ceramic materials, in 
polymeric scaffolds it is easy to chemically incorporate moieties that regulate cellular functions. 
Synthetic polymeric materials have been widely used in medical disposable supplies, prosthetic 
and dental materials, implants, dressings, extracorporeal devices, encapsulants, polymeric drug 
delivery systems, tissue engineered products and in orthopaedics (Tschon M, et al.,2007). 
Synthetic polymers can be made to exhibit predictable and reproducible mechanical and physical 
properties, such as tensile strength, elastic modulus and degradation rate, by fine controlling their 
chemical synthesis and processing, moreover, compared to metal and ceramic, they are easy to be 
fabricated into various shapes, with easy secondary processability and reasonable cost. Synthetic 
polymers have the advantage to be tailored to give a wide range of properties and more 
predictable uniformity, and they are generally free from the problems of immunogenicity, which 
can be a concern for naturally derived materials; moreover, synthetic polymers may contain low 
levels of chemical impurities (Gloria A, et al., 2010). 
In connection with biomedical polymers and depending on their behaviour after an implant or 
when in contact with biological fluids, polymers can be classified as biostable (do not degrade in 
vivo), and biodegradable types. The use of biostable polymers avoids the issue of matching the 
implant degradation rate with tissue regeneration, the biodegradable ones have the potential to 
produce an implant that, with time, is substituted by the living tissue. Biodegradable synthetic 
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polymers are widely studied and used in bone regeneration, they must degrade at a rate 
corresponding to the kinetics of neo-tissue formation and have gained preference over erstwhile 
popular synthetic polymers such as polymthylmethacrylate (PMMA) and polyethylene (PE).The 
most widely studied and most commonly used synthetic biodegradable polymers, for bone 
applications, are the polyesters poly(lactic acid) (PLA), poly(glycolic acid) (PGA) and poly(ε-
caprolactone) (PCL) all of which have their own advantages and disadvantages when used in bone 
applications (Table 4). Linear aliphatic polyesters are amongst the most popular materials for 
tissue fabrication, with a controlled degradation and the ability to entrap various drag molecules 
and yield materials of different strength. Polyglycolic acid (PGA) is a hydrophilic polymer with very 
fast degradation rate. It is a rigid thermoplastic material with high crystallinity (46-50%) and its 
degradation product is glycolic acid that is a natural metabolite. Because of the bulk degradation 
of PGA, there is a sudden loss of mechanical properties.  
Polylactic acid (PLA) is hydrophobic and persists for over a year in vivo. PLA exists in three forms: 
PLLA (L isomer), PDLA (D isomer) and racemic mixture (PDLLA) and the D isomer degrades more 
rapidly that the L isomer. PLA degrades to form lactic acid which is normally present in the body, 
entering in the Krebs cycle and excreting as water and carbondioxide. PLA is more hydrophobic 
than PGA and is more resistant to hydrolytic attack than PGA. PLA and PGA polymers and 
copolymers since 1970 are good candidates as fixation devices, scaffolds for tissue engineering, 
and for ligament and tendon reconstruction (Rezwan K, et al., 2006).  
Polycaprolactone (PCL) is a semicrystalline polymer that degrades at a much lower rate than PLA, 
indeed the homopolymer has a degradation time of the order of two to three years, it is non toxic 
with a tissue compatible material and has a propensity to form blends with a wide variety of 
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polymers. For this reason, PCL is used for developing long-term implantable materials (Salerno A, 
et al., 2009). 
 
Tab.4. Most important polymeric materials in bone tissue engineering. Biocompatibility, disadvantages and 
applications. 
 
POLYMERS BIOCOMPATIBILITY DISADVANTAGES APPLICATIONS 
Poly (lactic acid) 
Minimal cytotoxicity, 
Mild foreign body 
reaction, Minimal 
inflammation 
Local inflammation, 
random chain hydrolysis 
Skin; cartilage; bone; 
ligaments; tendons; 
vessels; nerves; bladder; 
liver 
Poly (glycolic acid) 
Minimal cytotoxicity, 
Mild foreign body 
reaction, Minimal 
inflammation 
Local inflammation, 
random chain hydrolysis 
Skin; cartilage; bone; 
ligaments; tendons; 
vessels; nerves; bladder; 
liver 
Poly (caprolactone) 
Minimal cytotoxicity, 
Mild foreign body 
reaction, Minimal 
inflammation 
Hydrophobic 
Skin; cartilage; bone; 
ligaments; tendons; 
vessels; nerves 
 
By blending these polymers in different ratios, materials with customized biological properties can 
be synthesized and another important advantage is the vast amount of chemical modification that 
can be applied to these polymers to get desired biocompatibility and cell-material interactions.  
To date a wide range of materials has been developed for fixation, repair and regeneration of 
tissues; depending on the applications and the tissue requirements, there are some cases where it 
is difficult to achieve all targeted properties from a single material. Consequently, great 
opportunities exist in the development of hybrid materials, which include more than one type of 
materials, often with the incorporation of a synthetic polymer component. Thus, the creative 
combination of natural and synthetic biopolymers, ceramics, and inorganic materials offers a 
convenient bridge between chemical and biosynthetic approaches (Gentile P, et al., 2011). 
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Composite scaffolds have been widely used in various medical applications and devices because 
regenerative medicine is a new filed with new requirements for smart materials, where 
composites have a strong role to play. Even though each individual scaffold has advantages for 
bone tissue engineering applications, each scaffold has disadvantages in various properties 
including the brittleness of calcium phosphate and the inferior mechanical properties of natural 
and synthetic polymers. The combination of different materials to form composites has led to 
overcome the disadvantages of any one particular scaffold. In fact, composites are considered to 
be materials consisting of two or more chemically distinct constituents that differ in form and 
chemical composition and are insoluble in each other, having a distinct interface that separates 
the constituents, and they are composed of one or more discontinuous phases embedded within a 
continuous phase. The discontinuous phase is usually harder and stronger and it is called the 
reinforcement or reinforcing material, while the continuous phase is termed the matrix (Gelinsky 
M, et al., 2007).  
They offer a variety of advantages over metals, ceramics and polymers, as they can incorporate 
the desirable properties of each of the constituent materials, while mitigating the more limited 
characteristics of each component. The properties depend upon the shape of the heterogeneities, 
upon the volume fraction occupied by them, and upon the interfaces among the constituents. The 
main benefit of using composite scaffolds is the ability to tailor their properties as per need, 
providing significant advantage over homogeneous materials (Simchi A, et al., 2011).  
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4.2 CHEMICAL AND PHYSICAL SCAFFOLD PROPERTIES 
Besides biological characteristics, the scaffolds may be bioactive because of the appropriate 
chemical and physical (topography and microstructure) properties.     
The way in which cells integrate with a scaffold is a more important property in tissue engineering 
applications and it is well established that cells interact with their environment through a number 
of sensors known as receptors, that may be transmembrane or intracellular and are coded to bind 
to specific molecules or ligands which mediate a specific intracellular response, such as 
proliferation, differentiation, gene expression, collagen synthesis or ion channels regulation. This 
phenomenon is known as cell signaling, where signaling molecules include ions, peptides or tissue 
or implant surface. The sequential process, initiated by binding of a signaling molecules, is known 
as signal transduction. Another form of cell interaction occurs through cell adhesion molecules 
(Nathan AS, et al., 2011).  
The chemical and physical properties of scaffolds are very important for processing and 
performance, as they are directly related to the mechanical and biological properties of the 
scaffolds. The nature of a scaffold’s surface determines its interaction with the body fluids, which 
contain several different kinds of proteins and this interaction leads to cascades of reactions, 
comprising the body’s response to the implant, determining the development of the tissue-
implant interface and long-term survivability. The surface properties of implant are important in 
order to address biocompatibility issues and the development of designs.  
Because it is difficult to produce scaffolds that possess the necessary bulk properties with a 
biocompatible surface, a scaffold’s surface can be modified in such a way so as to enhance its 
bioactivity, without sacrificing its bulk material properties. Many methods have been explored to 
modify the surfaces of scaffolds and all of them include some alterations of the chemical or 
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physical characteristics of the surface and can be accomplished by various means, such as ion 
beam processing, plasma surface modification, biochemical immobilization of biological molecules 
on the scaffold surface, or direct alteration methods such as etching or introduction of pores 
during fabrication of the scaffold. Modifying the chemical character of the surface often involves 
the changing of its hydorphobicity (Hutmacher DW, et al., 2007). 
Surface chemistry is a major component of the cell response to a scaffold surface. Surface 
chemistry modification, the physical coating of surface and the surface functionalization are 
readable by cells and tissues because all these methods modify the adsorption of proteins from 
biological fluids that intermediate with cells. The main approach currently used to control the 
surface chemistry is based on the coating of surfaces with a controlled materials layer of variable 
thickness going from several nanometers to several tenths to a lot of various chemical or physical 
deposition methods. Moreover, a surface could be functionalized by adsorption, grafting of 
peptides of biomolecules, deposition of layer-by-layer or polymer brushes.  
It is clear that optimizing the chemistry of a scaffold will greatly enhance the changes of a 
successful clinical outcome. It is believed that the surface chemistry of the scaffold dominates 
behaviour, through either the influence of its charge density and anatomic array on adherent or 
passing cell populations. In this regard, it is demonstrated that HA addition in the scaffold 
increases osteoblast proliferation and differentiation and reduces fibrous tissue encapsulation of 
implants exhibiting micromotion (Figure 12) (Borsari V, et al., 2005).  
Chemical composition of scaffold surface, may not only act directly on the bone or cells but may 
act influencing events such as angiogenesis prior to ossification or producing specific cytokines or 
signal molecules.  
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a  b  
Fig.12. Example of chemical surface on osteoblast morphology. a) Ti surface; b) the same Ti surface covered  with HA. 
(Images from Borsari V, et al., 2005). 
 
The sensitivity of bone cells and matrix proteins is not limited to chemical phenomena; bulk 
geometry, surface geometry and topography also influence the process of osteogenesis through 
mechanical and physical considerations that promote or screen the osteoconductive potential of a 
material. Geometrical structural features such as the volume fraction, size, shape and degree of 
interconnectivity of the pores that characterized the scaffold, and even the density or rigidity of 
the scaffold struts, have been found to influence the biological response. A shape memory 
behaviour has been helpful for scaffolds use in biomedical applications, because it improves 
mechanical, chemical and biological properties, which include the capability of resistance against 
in vivo degradation, decomposition and corrosion. It is also important that a scaffold should be 
easily and reproducibility processed into a desired shape and structure, which can be maintained 
after implantation, thus defining the ultimate shape of the regenerated tissue and, among 
materials, polymers show the higher capability (Hing KA, 2004).  
The roughness amplitude (or roughness height) should have intuitively a strong influence on cell 
response, but different if roughness amplitude is at the nano- or at the micro-scale. The roughness 
organization and morphology influence short-term and long-term adhesion, and proliferation 
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capacity of cells, on the other hand, cells are able to identify and respond differently to surfaces 
exhibiting different morphologies; for example disordered surfaces can stimulate MSCs 
differentiation in bone cells. The osteoinductivity of a scaffold is linked to the precise shape of 
surface concavities and this osteoinductivity occurs as a result of a concentration of some proteins 
such as BMPs within the surface concavities. On a smaller scale, surface texture has also been 
demonstrated to influence cell response to a material. Tissue differentiation and bone ingrowth 
are accelerated when the surface of the implant is coated with bioactive materials or through 
chemical and thermal treatments applied that convert the smooth to rough bioactive surface 
(Otsuki B, et al., 2006). Biocomposites, where one of the phases consists of inorganic particles, 
present a certain type of surface texture owing to the presence of these particles that may be fully 
embedded in the matrix or partially exposed in the material surface, generating specific surface 
topography depending on the geometry, dimensions and percentage of the inorganic phase. 
Although both micro- and nanotopography appear to have an important effect on protein 
adsorption and subsequent cell events, the complete picture and understanding of the 
relationship between micro- and nanotopography and cell response must be evaluated. An 
increase in cell number and attachment force has been reported on textured polymer substrates. 
A higher percentage of osteoblasts is inclined to attach to the rough surface, to synthesize 
extracellular matrix and mineralize. However, when the roughness level is greater than cell 
dimension it does not enhance cell response (Nathan AS, et al., 2011).  
Other physical properties, such as density, absolute density, porosity, microstructure, crystal 
structure and degree of cristallinity, specific heat, melting point and boiling point, are directly 
related to mechanical properties such as tensile strength, bending strength, compressive strength 
and hardness (Yu H, et al., 2008).  
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Evaluation of mechanical properties of scaffolds is important for matching material properties to 
the in vivo environment and this feature requirements are tied to specific applications. As about 
polymers, the poor mechanical strength of PLA, PGA and their copolymers has still been a 
bottleneck in creating load-bearing implants, although these materials are well known for their 
bioactivity and bioresorbability. By comparing the mechanical properties of the porous composites 
to those of porous polymeric scaffolds, a slight increase of mechanical properties is revealed. 
Dynamic mechanical tests are performed to determine time-dependent viscoelastic behaviour of 
polymeric scaffolds and mechanical properties, such as Young’s modulus, specific modulus, tensile 
strength, compressive strength, shear strength, yield strength, ductility and Poisson’s ratio, are 
critical to be evaluated before scaffold design and fabrication. It is well known that bone is 
functionally adaptive, i.e. that it responds to external mechanical stimuli to either reduce or 
increase its mass as required. Mechanical forces regulate many cell types, including both 
osteoblasts and osteocytes, through a process known as mechano-transduction that loosely 
describes the chain of molecular events that enable mechanical stresses to be converted into 
biological signals and physiological responses. Mechanical stimulation has been shown to 
stimulate osteoblastic differentiation of osteoprogenitor cells and it is possible to see how 
variation of local strain in scaffold struts, as a result of porosity variation, may induce or inhibit 
bone formation. Moreover, the evaluation of mechanical properties is important for the 
development of a temporary scaffold for tissue engineering purposes because the material must 
keep its crucial integrity during the first stages of the new tissue formation and undertake a 
progressive and gradual degradation (Sanz-Herrera JA, et al., 2010). The rate of degradation of the 
scaffolds must be balanced with the rate of tissue regeneration to maintain the integrity of the 
scaffold throughout its lifetime. The architecture of scaffold constructs, for tissue regeneration, 
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plays a very important role in cell in-growth, migration, maintenance and further structure of the 
new tissue. Pore distribution, interconnectivity and size distribution are key issues and scaffolds, 
that present a highly interconnected porous network, formed by a combination of macro, micro 
and even nanopores, enable proper tissue vascularization, nutrient diffusion and waste release 
(Armatas GS, 2006). 
 
4.2.1 Porosity 
Scaffold design and porosity (Figure 13) are key components for the success of an implanted 
device. For tissue engineering applications, an important aspect, in the design of scaffolds, is their 
required 3D porous architecture because porosity is important for the development of new tissue.  
Porosity is defined as the percentage of void space in a solid, is a morphological property 
independent of the material, plays a dominant role in the biomechanical characteristics, initial cell 
attachment and subsequent tissue regeneration and influences the bioactivity of a material 
because of the structure’s permeability. A scaffold should provide an open porous network to 
assure an uniform cell distribution and tissue regeneration, an appropriate transport of soluble 
signaling molecules, as well as nutrients and oxygen, and metabolic waste removal (Salerno A, et 
al., 2007), and this aim is reached by the combination of different pore sizes. Pores are necessary 
for bone tissue formation because they allow migration and proliferation of osteoblasts and 
mesenchymal stem cells, as well as vascularization. A porous surface improves mechanical 
interlocking between the implanted scaffold and the surrounding natural bone, providing greater 
mechanical stability at this critical interface (Hutmacher DW, et al., 2007). Although macroporosity 
(pore size>50 µm) has a strong impact on osteogenic outcomes, microporosity (pore size<10 µm) 
and pore wall roughness play an important role, contributing to higher bone-inducing protein 
 50 
 
adsorbtion. It is observed a greater degree and faster rate of bone penetration with increasing 
macroporosity because any new bone formation is strongly influenced by the degree of 
macroporosity.  
Microporosity has clearly been shown to have a significant impact on bioactivity with evidence to 
suggest that bioactivity is enhanced, not only through a combination of angiogenesis and cell 
adhesion, but also through the entrapment and adsorption of adhesion proteins or GFs within the 
micropores (Kilpadi KL, et al.,2004). Small pores favor hypoxic conditions and induce 
osteochondral formation before osteogenesis occurs. In contrast, larger pores rapidly become 
well-vascularized and lead to direct osteogenesis. Pore sizes of >300 µm and adequate porosities 
(80% for spinal fusion down to 60% for implant grafting in revision hip surgery) are best suited for 
successful regeneration of bone (Zhang C, et al., 2006). Although controversy, regarding optimal 
pore sizes for tissue engineering scaffold, exists a pore size of 200-600 μm is acceptable in most 
studies to provide adequate space for osteoblasts and vascular tissue ingrowth. 
A key feature for a porous scaffold is interconnecting porosity, which allows the cells to invade the 
scaffold, subsequently to proliferate and form extracellular matrix and to migrate throughout the 
entire scaffold. It is essential that the solid struts have an associated interconnecting micro/macro 
scale porosity for an optimized biological response (Bonfield W, 2006). 
Interconnected pores permit tissue and bone ingrowth, preventing loosening and retaining 
dynamic strength of implants.   
There is a need for controlled porosity, that would be the most suitable from a biological 
standpoint and this requirement must be balanced by the need to have an adequate compressive 
strength before the process takes place. The desire for high porosities must be tempered by the 
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need to maintain suitable mechanical properties within the scaffold throughout its lifetime (Hing 
KA, 2004).  
 
Fig. 13. Microtomographic image of a porous scaffold. (Image from laboratory of Preclinical and Surgical Studies-IOR). 
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5. AIM OF THE PROJECT 
Tissue engineering is a promising strategy to overcome the need to restore or regenerate tissues. 
In orthopaedic surgery, the autologous bone graft is widely recognized as the first choice material 
because its ability to promote osteogenesis, osteoconduction and osteoinduction in the site of 
injury and  its absolute and complete biocompatibility. Bone tissue, widely damaged by injury or 
disease, might also be replaced using constructs based on biocompatible materials and cells 
(Sundelacruz S and Kaplan DL, 2009). Recent advances in synthetic scaffold research give to us the 
possibility to investigate new solutions in the field of bone substitutes. Synthetic scaffolds, due to 
their non-biological origin, have no cross contamination risk, but there is the stringent need to 
study their biocompatibility and clinical behaviour (Weigel T, et al., 2006). Among synthetic 
materials, in recent years, studies of scaffold composite materials have been performed as to 
successfully reproduce the microenvironment required to support and improve the molecular 
interactions which occur within tissues, between cells and within the mineralized extracellular 
matrix. To date, polymer matrices reinforced by ceramic fillers such as hydroxyapatite represent a  
promising composite material, able to mimic the collagen/hydroxyapatite 
micro/macromorphology of “native bone material” (Frantzl P, 2007; Moroni L, et al., 2008).  
Scaffold design, porosity and early cell colonization are key components for the success of the 
implanted materials. It is well known that the scaffold architecture plays a crucial role in initial cell 
attachment and subsequent migration into and through the matrix and in the mass transfer of 
nutrients and metabolites, providing sufficient space for development and later remodeling of the 
organized tissue. Defined morphological features (i.e. pore size) are required to ensure cell 
adhesion, molecular transport, vascularization and osteogenesis and in order to study the scaffold 
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architecture and the 3D cellular distribution inside, among the best known techniques, 
microtomographic approach was validated in recent years (Takemoto M, et al., 2006). 
The aim of the present thesis was to comparatively investigate the in vitro and in vivo biological 
behaviour of new μ-bimodal polymeric, Poly ε-caprolactone (PCL), and composite, poly ε-
caprolactone/hydroxyapatite (PCL/HA), scaffolds for the treatment of bone defects.  
The scaffolds, fabricated with two different methods, gas foaming (GF) and selective polymer 
extraction (PE) from co-continuous blends (Salerno A, et al., 2009; Salerno A, et al., 2010), for PCL 
scaffold, and phase inversion/salt leaching for the composite PCL/HA scaffold (Guarino V, et al., 
2008; Guarino V, et al.,2009), were characterized by a new porosity (μ-bimodal porosity) and pore 
interconnectivity. 
During my PhD, at the Preclinical and Surgical Studies laboratory of Rizzoli Orthopaedic Institute of 
Bologna, microtomographic, in vitro and in vivo evaluations were performed, to assess the two 
scaffolds in terms of porosity, cell colonization of the scaffolds, biocompatibility, bioactivity, 
biofunctionality, biodegradability, and new bone formation. 
More precisely, before in vitro and in vivo studies, tests were conducted with a new 
microtomographic approach (Micro-CT, SkyScan 1172) to evaluate the overall porosity, 
macroporosity and microporosity of these new kinds of scaffolds, at rest and after three different 
compression stages (1 mm, 3mm and at maximum compression of 222N).  
Moreover, a visualization and a quantification of the distribution of cells through the entire PCL 
scaffold were evaluated with Micro-CT technique, after the seeding of cells (MG63) on the 
scaffold, because in literature, porous scaffolds with novel porous architecture should promote 
and guide the in vitro and in vivo adhesion, proliferation and 3D colonization of cells.  
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Subsequently, in vitro and in vivo tests, for the evaluations of cytotoxicity, biocompatibility, 
bioactivity, biofunctionality and biodegradability of the scaffolds were carried out with 
osteoblastic-like cells (MG63) and by implantation of the two scaffolds in rabbit bone defects.   
The defect healing and the new bone growth were calculated with static and dynamic 
histomorphometric parameters.  
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6. TESTED SCAFFOLDS 
In this thesis, for the regeneration of bone defects, the “in situ tissue regeneration” approach was 
taken into consideration and two scaffolds were investigated: a polymeric poly ε-caprolactone 
(PCL) and a composite poly ε-caprolactone/hydroxyapatite (PCL/HA) scaffold.  
PCL and PCL/HA were manufactured by researchers from the Interdisciplinary Research Centre on 
Biomaterials, CRIB and the Institute of Composite and Biomedical Materials, National Research 
Council, respectively, from University of Naples Federico II. These research groups have also 
performed chemical-physical tests on the scaffolds (Salerno A, et al., 2009; Salerno A, et al., 2010; 
Guarino V, et al., 2008; Guarino V, et al., 2009). 
 
6.1 PCL MANUFACTURE AND CHARACTERIZATION 
The bio-inspired design of micro- and nano-structured materials for, tissue-engineered scaffolds, is 
strongly driven by the increasing demand to recreate an extracellular matrix–like three-
dimensional (3D) substrate, facilitating more physiological growth of cells and final tissue 
regeneration. 
However, the need to drive the biological events, that underpin the regenerative processes 
associated with therapy of tissue diseases, imposes constraints on the design of innovative 
scaffold materials. An essential attribute is the ability to encode the required biological signals 
within the scaffold, so that most of the processes involved in cell response (i.e., adhesion and cell 
migration, proliferation and differentiation) may be controlled. 
Currently, such approaches mostly rely on the use of synthetic polymers such as poly(lactic acid) 
and PCL. They are used because of their ability to support, for long periods, the environmental 
stresses imposed on the pore walls by loads and the hydrostatic pressure of biological fluids 
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arising from the slow degradation kinetics found in vitro as well as in vivo (Guarino V, et al., 2007). 
Among polyesters, PCL has a long history in bone tissue engineering, mainly because it was shown 
to possess sufficient strength and stiffness to function for the period required by bone to heal.  
The matrix made of PCL, a polymer hydrolytically degradable both via bulk and surface erosion, 
guarantees degradation kinetics slower than other aliphatic polyesters such as poly(glycolic acid) 
or poly(L-lactic acid), because of its strong hydrophobic nature, offering a valid mechanical support 
for long-term implantation (Guarino V, et al., 2007).  
In this thesis, the μ-bimodal PCL scaffold was prepared by a combination of gas foaming (GF) and 
selective polymer extraction (PE) from co-continuous blends, as described by Salerno A (Salerno A, 
et al., 2009; Salerno A, et al., 2010). 
As schematically illustrated in Figures 14, the GF–PE technique is characterized by three different 
steps:  
(1) 3/2 (w/w) PCL (Mw=65 kDa and Tm 59°C-64°C) and thermoplastic gelatin (TG) co-continuous 
blend was prepared by melt mixing in an internal mixer (Rheomix® 600 Haake, Germany) at 60°C 
and 80 rpm for 6 min (Fig. 14A);  
(2) the PCL/TG blend was subsequently gas foamed with a 4/1 (v/v) N2/CO2 blowing mixture, at a 
foaming temperature (TF) of 44°C and with a pressure drop rate (PDR) of 700 bar s
-1 (Fig. 14B);  
(3) finally, the TG was selectively extracted from the foamed blend by soaking the sample in dH2O 
at 38°C for 1 week (Fig. 14C).  
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Fig. 14. Correspondence between the processing step and the microstructural evolution of PCL/TG system: (a) SEM 
micrograph of 3/2 (w/w) PCL/TG co-continuous blend after the selective extraction of the TG; (b) SEM micrograph of 
PCL/TG blend foamed with 4/1 (v/v) N2/CO2 blowing mixture, at TF=44°C and PDR = 700 bar/s; (c) SEM micrograph of 
µ-bimodal PCL scaffold prepared by the selective extraction of the TG from the foamed PCL/TG blend. (Image from 
Salerno A, et al., 2009) 
 
The most important microstructural and mechanical characterization, performed by Salerno A, et 
al., are summarized as follows:  
- the morphology, porosity, mean pore size and pore size distribution of PCL were evaluated 
by scanning electron microscopy (SEM) (S440; LEICA, Germany) and image (Image J®) 
analyses. The scaffold was cross sectioned, gold sputtered and analyzed at an accelerating 
voltage of 20 kV. Than the SEM micrographs were converted to binary images and analyzed 
by the Image J software. The overall porosity was determined by the equation:  
%porosity=[1-( ρS/ ρPCL)]x100 
 where ρS is the apparent density of the scaffold calculated from mass and volume 
measurements. The mass was calculated by a high accuracy balance (10-3g, AB104-S, 
Mettler Toledo, Italy), while the volume by geometrical calculation. The overall porosity 
results represent the mean value of five different porosity measurements. Image analysis 
was used to assess the volume fraction of the two different porosities by means of area 
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fraction measurements. The area fraction of the TG foamed phase provided the 
macroporosity volume fraction, while the difference between the mean overall porosity 
and the macroporosity amount yielded the microporosity volume fraction. Image analysis 
was also used to evaluate the mean pore size of the microporosity, based on the ASTM 
D3576 method; 
- the static compression properties of PCL were determined using an Instron mechanical 
testing system (4204, Instron, Italy), working at a cross head of 1 mm/min and with a 1 kN 
loading cell. Five disc-shaped scaffolds were tested and the elastic compression modulus 
(E) and compression yield strength (ςγ) were determined as the slope of the initial linear 
portion of the stress versus strain curve and the modulus slope at an offset of 1% strain, 
respectively; 
- wettability tests were performed by a Contact angle System OCA20 (Dataphysics) to 
evaluate the effect of the microarchitecture of PCL on fluid perfusion. A 0.2 µL water drop 
was poured onto the scaffold and the wetting time (for complete fluid penetration) results 
were divided in 3 groups: FAST (wetting time <3 s), MIDDLE (from 3 to 10 s), and SLOW 
(higher than 10 s). Forty measurements were performed for the scaffold. 
The process started from the preparation of a PCL  and TG co-continuous blend, with a PCL weight 
fraction of 60%. After the extraction of the TG from the PCL-TG blend, the co-continuity of the 
gelatin phase was evident from SEM micrograph. Following the gas foaming process, due to the 
incompatibility of the PCL/TG blend and to the different foaming behavior of the 2 polymers, the 
microstructure of the PCL/TG foam was characterized by two different porous phases, with the 
PCL foamed phase characterized by a 40 µm mean pore size and a high degree of pore 
interconnection. The final removal of the TG from the foamed blend allowed the formation of an 
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additional porosity, characterized by elongated and highly interconnected macroporosity with a 
rounded and smaller microporosity induced by the GF step (Figure 15). 
The value of overall porosity was about of 60%, uniformly distributed between the macroporosity 
(312 µm mean pore size), created by the selective extraction of the TG and microporosity (40 µm 
mean pore size), induced by the GF process.  
The results of the mechanical characterization showed the typical stress-strain curve of porous 
materials, undergoing static compression testing, with an initial linear-elastic region followed by a 
short collapse plateau and, finally, the steep increase in the stress values. Moreover, the 
calculated average compression modulus and yield strength were 11.4 and 1.6 MPa, respectively. 
Nearly 80% of the wetting times measured was almost equally distributed in the FAST and SLOW 
ranges (mean wetting time=1.66±0.88 and 16.26±6.06 s, respectively), whereas the remaining 20% 
was in the MIDDLE range (Salerno A, et al., 2009; Salerno A, et al., 2010). 
 
Fig. 15. Low magnification SEM micrographs of the µ-bimodal PCL scaffold. (Image from Salerno A, et al., 2010). 
 
However, PCL alone is not adequate as a bone substitute, because it does not promote an 
osteogenic response, one of the main requirements in the designing an ideal bone analogue to 
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guide the cascade of biological events related to the formation of mineralized tissue (Ang KC, et 
al., 2007).  
6.2 PCL/HA MANUFACTURE AND CHARACTERIZATION 
Today, it is taking up the improvement in osteoconductivity through the employment of insoluble 
signals (bioactive phase) integrated with the degradable polymer matrix (Wang M, 2003).  
The need for a mechanically functional material for bone substitution has generated numerous 
composites of calcium phosphate–reinforced polymers (Hutmacher DW, 2000). These act as 
reinforcement agents as well as osteoconductive signals, offering a valid compromise between the 
mechanical response and bioactivity of the scaffold. In particular, the challenging idea of designing 
‘‘tissue-inspired composite materials” has moved towards the synthesis of ceramic/polymer 
composites with advantages over either pure ceramic or pure polymer (Catauro M, et al., 2006), 
resulting in superior materials for specific applications.  
Traditionally, calcium phosphate-based ceramics have proved to be attractive bioactive materials 
for biological applications. It was proposed the use of calcium phosphates such as HA 
(Ca10(PO4)6(OH)2) with an atomic ratio of calcium to phosphorus (Ca/P) of 1.67 to stimulate a 
biochemical response from living tissues and to obtain a strong bond between the scaffold and the 
adjacent tissue with positive results.  
As also reported by Khan et al. and Chim et al. the combination of calcium phosphate, which on its 
own is brittle and limited in its applications, and polymer is also well founded as the addition of 
the polymer can impart beneficial properties such as mechanical toughness, resistance to brittle 
failure, and formability to the calcium phosphate (Khan YM, et al., 2004; Chim H, et al., 2006). 
In this thesis, PCL/HA scaffolds were developed with phase inversion/salt leaching method using 
NaCl crystals as porogen agent (Guarino V, et al., 2008). The scaffold of this thesis, showed a HA 
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relative volume fraction of 13% because it exhibited good mechanical performance than the other 
types, creating a good compromise between mechanical and bioactivity features, more important 
in the orthopaedic field.  
Briefly, PCL pellets (MW 65 kDa; Sigma Aldrich, Milan, Italy) were dissolved in a 20 wt % N-N-
dimethylacetamide ( J.T. Baker 06/2007) solution (5 g polymer in 20 ml solvent) by stirring for 
about 3 h at 58°C. Subsequently, NaCl crystals (sieved into specific size range of 212–300 μm) were 
homogeneously mixed to the polymer solution with a volume ratio of about 9/1, and the mixture 
was poured in the Petri dish and compressed by 0.127 N/mm2 for 10 min, for a more uniform 
distribution of porogen agent into the polymer mixture. The mixture was then dipped in ethanol (3 
ml each 20 min for three times) at room temperature and in bidistilled H2O (Carlo Erba, Milan, 
Italy) for 7 days, with three changes a day. The HA powder was added to the PCL solution (29% 
w/w) before the solvent extraction. In particular, HA particles showed a three-modal dimension 
distribution (d0.1 0.42; d0.5 4.02 and d0.9 11.91 μm), with a specific surface area of 13.29 m
2/g and a 
theoretical density of 3.16 g/cm3.  
Some tests were performed, by Guarino V, et al. (Guarino V, et al., 2008), to assess the 
morphological and mechanical behaviour of the scaffold, and some of these techniques and 
results are summarized as follows: 
- morphological investigation was studied by Scanning Electron Microscopy (SEM)/Energy 
Dispersive Spectroscopy (EDS) analyses. For SEM (Leica Stereoscan mod.420-Oxford 
Intsruments), scaffold was gold-coated using a sputter coater set at 15 mA for 20 min. EDS 
was performed (Oxford mod. INCA 200) to measure the energy and intensity distribution of 
X-ray signals generated by the electron beam striking the surface of the specimen. As 
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consequence, the elemental composition at a point, along a line, or in a defined area can 
be easily determined with a high degree of precision (nearly 0.1 wt%);  
- thermogravimetric analysis (TGA) (TA instrument TGA model 2950) was used to verify the 
weight percentage of HA, using a nitrogen atmosphere with a temperature 20-500 °C; 
- compressive mechanical properties were evaluated at room temperature on 
dynamometric machine (Instron 4204) with a 100 N load cell and a crosshead speed of 1 
mm/min. The elastic modulus E was calculated by the initial slope of the stress-strain curve 
before the plateau region. Tensile properties were performed at room temperature by an 
Instron machine according to the ASTM 638/2a standard, using the same load cell and a 
crosshead speed of 1 mm/min. The elastic modulus E was evaluated by the slope of the 
stress-strain curve in the strain range of 0-0.1 mm/mm. The study was carried out through 
analysis of five samples of the scaffold;  
- mercury intrusion porosimetry (Thermo Electron Pascal 140-240) was used for the 
evaluation of pore size distribution and it is based on the Washburn equation:  
p.r= - 2γ.cosθ 
where p is the applied pressure, r is the radius of the pore, γ  is the surface tension of the 
mercury, and θ is the contact angle between mercury and polymer. In this case, cylindrical 
shape of pores and constant pressure were assumed. A mercury surface tension of 480 
mN/m and a contact angle of 141.38° were used for all measurements while pmax applied of 
400 Pa and 200 KPa were chosen in connection with pore size analysis. This method 
provided simultaneously the total porosity, the average pore diameter, and the pore size 
distribution into 3D scaffolds. In addition bulk density, apparent density and specific 
surface were evaluated.  
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A typical bimodal porosity has been evidenced: a macroporosity (20-300 µm), due to the 
extraction of the sodium chloride crystals, and a microporosity (1-20 µm), ascribed to 
solvent/nonsolvent exchange, were observed (Figures 16). Since the PCL component underwent 
thermal degradation between 350 and 420°C, the effective HA weight percentage has been 
evaluated through residue determination at 500°C.  
In particular, average residual products of 34.8 were found. The weight loss (%) is a function of 
temperature.  
EDS confirmed the presence of stoichiometric HA (Ca/P atomic ratio=1.66) distributed in the 3D 
structure on the cross section of scaffold. The same value of Ca/P atomic ratio was achieved both 
on surface and cross-section.  
With mercury intrusion porosimetry technique, an overall porosity of 92.12%, an average pore size 
of 129.3 µm, a bulk density of 0.134 g/cm3 and a total specific surface area of 0.464 m2/g were 
observed. The highest volumetric fractions of pores fall in the range of 20–200 µm. 
As about mechanical properties, the tensile elastic modulus was about 1.31 MPa, with a Strain at 
maximum stress of 0.164 mm/mm and a maximum stress of 0.076 MPa. The compressive Toe 
region Elastic Modulus was of nearly 0.318 MPa. A PCL scaffold, used for comparison, showed an 
elastic modulus of 1.10 MPa, a strain at maximum stress of 0.160 mm/mm, a maximum stress of 
0.060 MPa and a compressive Toe region Elastic Modulus of 0.258 MPa. 
In another subsequent study, Guarino V, et al., compared PCL/HA 13% (the composite material 
used in my thesis) with pure PCL (Guarino V, et al., 2009). 
The in vitro degradation mechanisms and kinetics of PCL and, especially, of the PCL added with HA, 
were evaluated by immersing materials in 3 different aqueous media, at 37°C: PBS at pH 7.5; 0.01 
M NaOH solution; and SBF buffered at pH 7.5. For each degradation time (28 and 56 days), the 
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samples were recovered, washed with distilled water, vacuum-dried at room temperature, and 
weighed before being subjected to the various analyses. 
 
 
Fig.16. Bimodal porosity of the scaffold. A) Macroporosity due to the salt removal, B) microporosity due to the phase 
inversion mechanisms. (Image from Guarino V, et al., 2009). 
 
The weight loss percentage of the samples was calculated according to the equation:  
% weight loss= 100 (ω0-ωt)/ω0 
Raman spectroscopy and thermal analyses were also performed. The Raman spectra of the 
untreated and in vitro degraded samples were recorded on a Jasco R1100 spectrometer with a 488 
nm radiation from a Spectra-Physics argon ion laser source. The spectral resolution was 4 cm-1, 
and laser power at the sample was nearly 40 mW.  The thermogravimetry (TG) thermograms of 
the untreated and in vitro degraded scaffolds were performed using a Mettel TA-STAR, TGA/SDTA 
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851e thermobalance, in air with a heating rate of 2°C/min, from 25 to 1000°C. The PCL content was 
evaluated through the weight loss in the 200-500°C range. The DSC Thermograms of the untreated 
and in vitro degraded samples, were performed with a Mettler TA-STAR, DSC 821e calorimeter, 
covering 5-120°C. The samples were heated at 2°C/min and then cooled at -2°C/min.  
Briefly, results showed that the polymer phase in the untreated (not degraded) PCL/HA scaffold 
appeared more crystalline than in the pure PCL sample. Specifically, an increase of crystallinity 
from 71% (PCL) to 74% (PCL/HA) was observed, with a lower amount of amorphous regions. In the 
case of PCL/HA, degradation proceeded more slowly compared to pure PCL, due to the higher 
values of crystallinity. However, the behaviour of PCL/HA 13% suggests that crystallinity cannot be 
the only parameter that determines the degradation kinetics of the composite. Although the 
PCL/HA 13% was characterized by a cristallinity quite similar to pure PCL, the net weight loss 
percentage of the composite, after 56 days of degradation in NaOH solution, was significantly 
lower than that of the pure PCL under the same condition, being 0.9% versus 15%, respectively. 
These results lead to the conclusion that the HA component plays a significant and complex role in 
the inhibition of degradation (Guarino V, et al., 2009).  
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7. MICROTOMOGRAPHY (MICRO-CT) 
Before the explanation of the methodology for the scaffold microtomographic analyses, a brief 
description of the microtomography is reported.  
Microtomography is based on the same principles of a normal X-ray tomography used in clinical 
medicine but avails itself of a microscopic level resolution. This type of equipment allows images 
to be obtained of the internal structure of a small object with high spatial resolution and high 
speed, without sample preparation or chemical fixation.  
Typically, the spatial resolution of conventional medical CT-scanners is in the range of 1 - 2.5 mm, 
which corresponds to 1 -10 mm3 voxel (volume element) size. Computerized X-ray microscopy and 
microtomography now give possibilities to improve the spatial resolution by seven to eight orders 
in the volume terms. The system “SkyScan 1172", used in this thesis, allows to reach a spatial 
resolution of 5 µm corresponding to near 1x10-7 mm3 voxel size. As in the “macro" CT-scanners, 
the internal structure can be reconstructed and analyzed fully non-destructively (Ohgaki T, et al., 
2006). 
The SkyScan 1172 (Figure 17) is a high resolution X-ray Micro-CT system with an architecture in 
which both the sample stage and the X-ray camera are moveable. This allows a good combination 
of image resolution, sample size accommodation, scan speed, and sample throughput. The flexible 
scanner geometry is particularly advantageous over intermediate resolution levels, where scans 
are around ten times factor compared to previous scanners with a fixed source-detector design. 
Table 5 summarizes the main principal features of  Skyscan 1172. 
Micro-CT is extremely helpful when it comes to characterize devices in the preimplant phase and 
evaluating possible deformations and/or degradations after the explantation phase, moreover it is 
useful for the analysis of both tissue engineering scaffolds and bone tissue regeneration after the 
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preclinical application of innovative biomaterials and biocomposites (Stock SR, 2008). Micro-CT 
shows some advantages over the classical histology, such as the maintenance of the integrity of 
the analyzed specimen, the lower acquisition time and the higher number of analyzed sections 
than histology and the possibility to perform 3D studies. Moreover, Micro-CT possesses 3 stages, 
the cooling, the material testing or compression chamber and the micro-positioning stages 
(Figures 18). The first is  useful for in-situ object scanning during specific temperature  and it 
contains all necessary parts to cool down a sample, measure and stabilize the sample stage 
temperature. An object can be scanned in any selected temperature in the range of approximately 
+30°C to -20°C. The second is used for compression and tension tests and it permits to scan an 
object during mechanical tests, contains useful parts for compression and tension and permits to 
measure the load applied.  The third, is applyed for the correct centering and positioning of more 
little specimens for the different phases of scan, acquisition and reconstruction.   
                                      
Fig.17. Micro-CT Skyscan 1172. 
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a              b        c   
Fig.18. The three stages of Micro-CT: a) the cooling, b) the material testing or compression chamber and c) the micro-
positioning stages. 
 
Tab.5. Characteristics of Micro-CT Skyscan 1172. 
 
 CAMERA 10 MEGAPIXEL 
SPECIMENT MAX SIZE 6 cm Ø, ca 6 cm h 
SPOT SIZE <5µm@4W, 20-100KV, 0-250 µA 
X-RAY SOURCE sealed microfocus X-ray tube, air cooled,>10000h lifetime 
RESOLUTION 5 µm 
PIXEL SIZE (MAX.MAGNIFICATION) <0.9 µm 
N° OF PIXELS 4000X2300 
RECONSTRUCTION TIME 6.8 sec per cross section 1024x1024 pixels 
RECONSTRUCTION ALGORITHMS Cone-beam volumetric reconstruction 
OPERATION CONDITIONS -10°C+50°C storage, 18°C-25°C operation, 70% humidity max 
SMALLEST DETAIL DETECTABILITY ~1 µm 
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Briefly, in Skyscan 1172, the system obtains multiple X-ray shadow transmission images of the 
object from different angular views, as the object rotates on a high-precision stage (Acquisition 
step). From these shadow images, cross section images of the object are reconstructed by a 
modified Feldkamp cone-beam algorithm, creating a complete 3D representation of internal 
microstructure and density over a selected range of heights in the transmission images. For the 
reconstruction one can use a volumetric (cone-beam) reconstruction of one, several, or all cross 
sections or a region of interest (ROI) reconstruction. After the serial reconstruction, one can 
display the cross sections onto the screen as well as reconstruct a realistic 3D-image with 
possibilities to “rotate" and “cut" the object model. On this model the internal morphological 
parameters can be calculated. Moreover, it is also possible to create virtual 3D models of the 
analyzed samples, that are very useful for a complete visualization and understanding of inner and 
outer morphology of a scaffold. CT-analyzer (CTAn) is a dictate application for deriving quantitative 
parameters and constructing visual models from scanned datasets obtained with SkyScan Micro-
CT instruments.  Morphometric parameters are calculated by CT-analyzer either in direct 3D based 
on a surface-rendered volume model, or in 2D from individual binarized crossection images. 
Further, for both 3D and 2D measurements, there are two types of analyses. Firstly, all objects in 
the selected region can be analyzed together, and the integrated results can be calculated, such as 
total volume or surface of all objects, or mean thickness of all objects, etc. Secondly, individual 
“discreet” objects can be categorized, on the basis of being entirely surrounded by space either in 
2D (on a single crossection only) or in 3D (for a selected volume comprising many crossectional 
levels). Morphometric parameters in 3D and 2D can be carried out on all the individual objects.  
All calculations are performed over a selected region. Consistent and accurate selection of the 
regions or volumes of interest is fundamentally important to obtaining accurate and meaningful 
 70 
 
data. Some clarification of terminology for this is useful. The term “region of interest”, or ROI, 
refers to a selected region of a single crossectional image and 2D analysis is performed within a 
ROI. The “volume of interest” (VOI) refers to the collective sum of all ROIs over a contiguous set of 
crossectional image slices, representing a selected 3D volume. In Figure 19 the Micro-CT working 
steps are summarized.   
All measurements of morphometric parameters in 3D and 2D are performed on segmented or 
binarized images (Tables 6). Segmentation or “thresholding” must be done prior to morphometric 
analysis.. Parameter names follow two alternative nomenclatures, “General Scientific” or “Bone 
ASBMR”, the latter based on Parfitt et al. (1987). Parfitt’s paper proposed a system of symbols for 
bone histomorphometry, and the principles of Parfitt’s system are applied here to both the Bone 
(ASBMR) and the General Scientific parameter names (Parfitt AM, et al., 1987-A).  
 
 
Fig.19. Scheme of  Micro-CT working steps. 
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Tab.6. 2D and 3D parameters calculated by Micro-CT. 
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7.1 MICRO-CT EVALUATION OF SCAFFOLD POROSITY: MATERIALS AND METHODS 
Three samples of each scaffolds (PCL and PCL/HA) with 5 mm in diameter and 5 mm in height, 
were used for the microtomographic evaluations of the morphological characteristics such as 
porosity and the behaviour of the scaffolds during biomechanical tests, evaluating the changes of 
porosity during compression steps.  
The Micro-CT tests were divided into 2 steps:  
The first step was to carry out an acquisition of the two scaffolds with the Micro-CT system 
Skyscan 1172, to evaluate total porosity, macroporosity and microporosity. 
The acquisition of both scaffolds was made without using any metallic filter between the X-ray and 
the sample, with a source current of 167μA and a source voltage of 60kV. Both samples were 
rotated until 360 degrees with a rotation step of 0.30 degrees and a frame averaging of 3. The 
image pixel size was 3.60 μm. Moreover, the acquisition step had a duration of 1 hour. 
The images, obtained from acquisition, were later reconstructed by the software NRecon (version 
1.4.4) without any correction but with the specific post-alignment depended on acquisition and 
undersampling 1, with images dimension of pixel of 2.5 µm. 
The images datasets were analyzed by CTAn (1.9.2.5. version) to evaluate 3D and 2D total 
porosity, macroporosity, microporosity and interconnectivity. The reconstructed images 
represented the entire volume of the sample.  
In order to do that, a cylindrical volume of interest (VOI), totally enclosed in the scaffold, was 
considered, excluding lateral edges and some slices on the top and on the bottom of the scaffold. 
Then the images were binarized, considering the biomaterial plot as the object (white).  
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After binarization the 2D total porosity was calculated with the formula: 
 
where N is the number of analyzed sections, T.Ar is the total Region of Interest Area and Obj.Ar is 
the object Area. The 3D porosity was calculated as the ratio between the total pore volume and 
the total volume of interest, whereas the interconnectivity was calculated as the largest volume of 
a single 3D pore detected, compared to the total pore volume. 
The 2D distribution of pores and the number of pores throughout the entire volume of the sample 
were also evaluated. Using these data a count  of macro and micro porosity for each scaffold was 
checked. 
In the second step the mechanical tests of compression of both scaffolds were done. 
The materials were positioned between the two plates of the compression chamber (Figure 18b) 
and a load started to be applied. After a displacement of 1mm, 3mm and at maximal compression, 
corresponding to 222N, the compression was temporarily interrupted to make acquisition. 
The load was measured by an accurate tension/compression load cell. The sample should be put 
on the lower disc of the compression chamber, that is the part that will move up when the 
specimen is being compressed. The same values of acquisition and reconstruction of the first step 
were used and the graphs of load/displacement of the analyzed samples were recorded.  
Also in this case, the obtained datasets of reconstructed images were analyzed by CTAn to 
evaluate the porosity and the same kind of VOI totally enclosed in the scaffold was used. 
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7.2 MICRO-CT SURFACE VISUALIZATION AND QUANTIFICATION OF CELLS ON THE 
PCL SCAFFOLD: MATERIALS AND METHODS 
Micro-CT approach was used to observe cell-scaffold interaction in term of cell surface 
localization, visualization and colonization through the entire PCL scaffold and to make a direct 
comparison of the microtomographic sections with the Scanning Electron Microscopy (SEM) 
images of the surface.  
Before cell seeding, cylindrical PCL scaffolds were divided into 2 equal pieces and sterilized by 
soaking in 70% ethanol (overnight), then in 1% antibiotic/PBS solution (2 hours). Finally, the 
materials were washed with PBS and pre-wetted in complete medium for 1 hour, to permit 
proteins adsorption, to promote material hydrophilicity and then cell adhesion onto PCL. A culture 
of MG63 was used and maintained in DMEM medium (SIGMA, St.Loius, MO), containing 10% fetal 
bovine serum (FBS), 2 mm L-glutamine, 100 units/ml penicillin and 100 μg/ml streptomycin in 
saturated atmosphere (5% CO2/95% air), at 37°C. The cells were subcultured in flasks, detached by 
0.25% trypsin/EDTA (GIBCO, Invitrogen, NY, USA) seeded dropwise in 20 μl of medium onto 0.25 
cm2 PCL surface, and placed in 24-well plates (Costar, NY, USA). This procedure allowed cell 
adhesion to the surface of the materials, infiltration into the porous structure and also prevented 
cell dispersion. After 1 hour, each scaffold was carefully removed into a new 24-well plate and 
covered with 1 ml of complete medium. Three samples of PCL scaffold were placed in replicate. 
The MG63 cell line was seeded at different densities: 1x105 cells/cm2, 2x105 cells/cm2 and 4x105 
cells/cm2. Two different experimental times, 1 week and 2 weeks, were selected for the analysis of 
the MG63 colonization. Furthermore, PCL without cells was used as negative control, with the 
same culture conditions as the seeded constructs and the same endpoints. 
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The specimens were analyzed by Micro-CT before gold-coating and the subsequent SEM analysis. 
Cells haven’t the intrinsic X-ray attenuation ability so they aren’t seen with Micro-CT technique, 
thus it becomes necessary to use a contrast agent. Osmium tetroxide (OsO4) was used because of 
its great affinity with lipids: it reacts with unsaturated lipids by forming black compounds 
containing hexavalent osmium that are visible by Micro-CT (Metsher BD, 2009). 
Each specimen was scanned at a source voltage of 30 Kv and a source current of 175 μA, without 
filters. The samples were rotated to 180 degrees with a rotation step of 0.4 degrees and a frame 
averaging of 4. The pixel size was 2.5 μm and the scan duration was nearly 1 hour. The scanning 
dataset, obtained after the cone beam acquisition, consisted of approximately 500 images in 16-
bit tiff format (4000 X 2096 pixels). The acquisition images were later reconstructed by the 
software NRecon (1.6.2.1. version) without corrections except for the specific misalignment for 
each acquisition and an accurate ring artefact reduction because of the small rotation step and the 
small pixel size. The image datasets in 8-bit jpg format (1000 images 4000 X 4000 pixels) were 
visualized with DataViewer software (1.4.3 version) to identify surface sections and to allow the 
direct comparison with SEM surface images.  
The threshold value for image segmentation for quantification and relevant distribution of seeded 
cells was chosen according to attenuation histograms of the sample X-rays, i.e. scaffolds cultured 
with MG63 at 1 week and 2 weeks and scaffolds without MG63 at the same experimental times. 
The attenuation histograms of the samples referred to a cylindrical volume of interest (VOI) with a 
diameter of 4 mm and a height of 1.5 mm for each sample analyzed and placed within the 
scaffold. This VOI was placed so that it was included inside the sample and had the first section 
made of air outside the scaffold itself as its upper limit. For quantitative analysis of the cells the 
CTAnalyzer (1.11.8 version) software program was used. The cell volume within the total volume 
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of the scaffold was calculated in 3D and the result was expressed as 3D cell density in percent. 
Differences between groups were compared using analysis of variance (ANOVA) and post hoc 
testing with Gabriel’s post hoc test.  
For SEM evaluations, the same cell-scaffold constructs, used in the previous Micro-CT tests, were 
fixed for 2 hours in 2.5% glutaraldehyde in 0.1 M cocodylate buffer at pH 7.2, at 4°C and then, they 
were dehydrated in graded series of ethanol and in hexamethyldisilazane. After gold-coating, the 
samples were used for the SEM observation by Stereoscan200, Cambridge. The images, obtained 
by the backscattered electron (BSE) technique were performed at 30 KV.  
 
7.3 MICRO-CT EVALUATION OF SCAFFOLD POROSITY: RESULTS 
The μ-bimodal PCL and PCL/HA overall porosity, macroporosity, microporosity and  
interconnectivity before the compression tests are summarized in Table 7. It was highlighted that 
the scaffolds were characterized by high interconnectivity and good mechanical responses.  
Tab.7. Overall porosity, macroporosity, microporosity and interconnectivity of the two scaffolds. 
 PCL PCL-HA 
OVERALL POROSITY (%) 45.3 ± 2.5 51.9 ± 2.5 
MACROPOROSITY(%) 49.7±1.2 67.3±2.3 
MICROPOROSITY (%) 50.3±0.7 32.7±3.4 
INTERCONNECTIVITY (%) 99.7±0.12 98.5±0.15 
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The variation of overall porosity of the polymeric scaffold, submitted to the mechanical tests, was 
evaluated by plotting the percentage of porosity for each slice through the volume for every step 
of compression analyzed, as depicted in Figure 20. 
a      
 
 b  
Fig.20. a) The 2D Micro-CT images of the PCL scaffold and b) the percentage of porosity through the volume for every 
analyzed compression steps. 
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It was noted a slight improvement in porosity in the first phase of compression due to an initial 
expansion of pores and then a progressive loss. 
Nearly the same results were obtained with the PCL/HA composite, as depicted in Figure 21. 
a       
b  
Fig.21. a) The 2D Micro-CT images of the PCL/HA scaffold. HA particles appeared like light grey dots. b) The 
percentage of porosity through the volume for every analyzed compression steps.  
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Moreover, the 3D and 2D analyses of overall porosity, at rest and after maximum compression, for 
both scaffolds were evaluated and the values are summarized in Table 8. 
 
Tab.8. 3D and 2D overall porosity of the two scaffolds at rest and after maximum compression. 
Sample 3D porosity (%) 2D porosity (%) 
PCL 45.3±2.5 44.5±0.3 
PCL max compression 21.7±0.8 21.2±0.7 
PCL/HA 51.9 ± 2.5 49.8±1.2 
PCL/HA max compression 21.8±1 21.3±1.3 
 
The distribution of 2D size of pores, comparing the decrease of pore dimension in the samples 
after compression, is observed in Figure 22. 
An improvement in the microporosity after the compression, in spite of an all-in loss of porosity 
was noted. 
The graphs of load/displacement obtained, gave us information on some of the mechanical 
properties of the materials and it was noted that adding HA there was no significant effect on the 
elasticity of the polymeric scaffold. The graphs are shown in Figure 23, where the red points 
represent every steps of compression in which Micro-CT evaluations were done.  
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Fig.22. Istograms of the distribution of 2D size of pores for PCL and PCL/HA scaffolds, before and after maximum 
compression. 
 
 
Fig.23. The load/displacement graphs for PCL and PCL/HA scaffolds. Red points represent every steps of compression 
in which evaluations were done. 
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7.4 MICRO-CT SURFACE VISUALIZATION AND QUANTIFICATION OF CELLS ON THE 
PCL SCAFFOLD: RESULTS 
SEM and Micro-CT images of the seeding surface of the cell/scaffold constructs are reported in 
Figures 24. As shown, the cells proliferated and almost uniformly colonized the surface of the 
scaffold. Furthermore, differences in cell proliferation were observed as a function of the starting 
seeding density. In particular both at 1 week and at 2 weeks after seeding, the grey level contrasts 
were stronger with a cell density of 1x105 cells/cm2 and 4x105 cells/cm2. Conversely, the images 
obtained from the 2x105 cells/cm2 seeding were less bright. Moreover, the distribution of the grey 
level contrasts was well defined and the cells, or the cell clusters, appeared as pointed shape.  
 
Fig.24. Images of samples surfaces seeded with MG63 cells at 1 week and at 2 weeks. L are SEM images, whereas R 
are Micro-CT sections. a,d: cell density of 1x10
5
 cells/cm
2
. b,e: cell density of 2x10
5
 cells/cm
2
. c,f: cell density of 4x10
5
 
cells/cm
2
.  
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The 3D results of cell density within the scaffold, expressed as ratio between the volume of cells 
detected and the total volume of the scaffold, showed an increase over time for all concentrations 
of seeded cells. At 2 weeks, the cell volume values increased significantly by 91% for scaffolds 
seeded with 1x105 cells/cm2, 178% for scaffolds seeded with 2x105 cells/cm2 and 119% for 
scaffolds seeded with 4x105 cells/cm2. Significant differences were found at 2 weeks between cell 
proliferation of the scaffolds seeded with 1x105 cells/cm2 and 2x105 cells/cm2 (p<0.05) (Figure 25). 
 
Fig.25. 3D cell density (%) of MG63 cells seeded on PCL scaffolds at different concentrations and  different 
experimental times.* means statistical difference between scaffolds at the same experimental time (p<0.05). 
 
The picture of the 3D models also showed the spatial distribution of cell colonization of the 
scaffold and provided a vision of the cell proliferation trend over time. The increase in cell number, 
shown by the increase in cell density within the scaffold, was thus detected more at the surface in 
scaffolds seeded at concentrations of 1x105 cells/cm2 and 4x105 cells/cm2, whereas seeding at a 
concentration of 2x105 cells/cm2 on the PCL scaffold was less evenly spread over time (Figure 26). 
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Fig.26. 3D models of PCL scaffolds seeded with different concentrations of MG63 cells at 1 week and 2 weeks after 
seeding.  
 
At 2 weeks, cells seeded with an initial density of 2x105 cells/cm2, were observed more inside the 
scaffold than on surface, confirming the previous results of SEM and Micro-CT surface images.  
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8. IN VITRO STUDY 
Based on the different kind of tissues in which the device will be implanted,  there are different 
models for the biocompatibility evaluation (UNI EN ISO 10993-1:2010). Among the first 
biocompatibility evaluation tests, cytotoxicity studies are developed to determine the in vitro 
biological response, using appropriate biological parameters  (UNI EN ISO 10993-5:2009). 
 
8.1 MATERIALS AND METHODS 
In the present study, all materials, were tested as cylinders (6 mm diameter x 2 mm height) and a 
human osteoblast-like cell line (MG63) was used. Before in vitro tests, materials were sterilized by 
γ-rays at 25 KGy (Gammarad, Bologna, Italy). Cells were cultured in sterile DMEM (with 10% foetal 
calf serum, 100 U/ml penicillin and 100 μg/ml streptomycin) at 37°C in a 95% air/5% CO2 
atmosphere. Cells at confluence were released with 0.05% (w/v) trypsin and 0.02% (w/v) EDTA, 
and counted with Trypan Blue exclusion dye (Sigma) in an Neubauer counting chamber. Briefly, 
cells were centrifuged at 1100 rpm for 5 minutes  and then resuspended in 1ml of medium. Ten µl 
of cell suspension were added to a solution of 50 µl of 0.4% Trypan Blue and 40µl of NaCl 0.9% and 
subsequently, ten µl of this solution were transferred in the Neubauer chamber and cells were 
counted under light microscope at 10x of magnification in four squares of the chamber. Died cells 
appeared blue, while viable cells were colourless. The viable cell number was obtained by the 
following equation:  
Viable cells= cell count/squares x dilution factor x 104  
where the dilution factor is 10 and 104 is the chamber area. 
A cell concentration of 1x105 cells /ml was seeded, in triplicate, in three 24-wells plates, on sterile 
materials to be tested (3 PCL and 3 PCL/HA materials for each plates).  
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The same amount of cells was seeded in empty wells as negative control (CTR). One ml of DMEM 
was added to all the wells. Plates were cultured in standard conditions, at 37°C with 95% humidity 
and 5% CO2 for 24 hours, 7 and 14 days (3 experimental times) and the medium was changed 
twice a week. At 24 h, medium was changed with DMEM additioned with β-glicerophosphate (10-8 
nM) and Ascorbic acid (50 mg/ml) to activate osteoblasts. For the production of osteocalcin the 
culture medium was enriched with 1,25(OH)2D3, 48 h before end of the experimental times. At 4 
and 24 hours, early evaluations of cell adhesion and morphology (neutral red staining), were 
tested, respectively.  The Lactate dehydrogenase release (LDH), also evaluated at 24 hours, is an 
indirect cytotoxicity parameter, because the release of this enzyme  is an index of the irreversible 
lysis of cellular membranes. At the end of experimental times the supernatants were collected and 
centrifuged to remove particulates, if any. Aliquots were dispensed in Eppendorf tubes for storage 
at -20°C for following quantitative tests: Bone-specific alkaline phosphatase activity (BAP), 
Osteocalcin (OC), Type I pro-collagen production (CICP) and Transforming growth Factor β1 (TGF-
β1), Tumor Necrosis Factor α (TNF-α) and Interleukin 6 (IL-6) release. All the measured 
concentrations were evaluated at 7 and 14 days and normalized by Total Protein (TP, Total Protein 
micro-Lowry kit, SIGMA). At 24 hours, 7 and 14 days, WST-1 proliferation test was performed to 
assess cell proliferation rate and a reduction of the vitality more than 30% than control is an index 
of cytotoxicity.  
 
8.1.1 Cell adhesion and morphology 
- Cell adhesion: After an incubation of 4 hours, to let the cells to adhere to the substrate, the 
medium with the non- adherent  cells was collected. The cells in suspension were counted and the 
results were given as percentage:  
Adherent cells=(seeded cells – non-adherent cells) x 100 
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-Cell morphology: A 0.033% solution of Neutral Red staining (Sigma, lot 57H2326) was added to 
culture medium of all wells for 90 min. Cultures were examined by microscopy (Olympus 
mod.1X71) at 10 and 4 x of magnification for the evaluation of cell morphology and explanatory 
images were selected. The cell morphology was evaluated by the following qualitative score 
(Qualitative morphological grading cytotoxicity-ISO 10993-5:2009 E) in Table 9. 
Tab.9. Qualitative morphological grading of cytotoxicity  
Grade Reactivity Conditions of all cultures 
0 None Discrete intracytoplasmatic granules, no cell lysis, no reduction of cell growth. 
1 Slight Not more than 20% of the cells are round, loosely attached and without 
intracytoplasmatic granules, or show changes in morphology; occasional lysed cells 
are present; only slight growth inhibition observable. 
2 Mild Not more than 50% of the cells are round, devoid of intracytoplasmatic granules, 
no extensive cell lysis; not more than 50% growth inhibition observable. 
3 Moderate Not more than 70% of the cell layers contain rounded cells or are lysed; cell layers 
not completely destroyed, but more than 50% growth inhibition observable. 
4 Severe Nearly complete or complete destruction of the cell layers. 
 
8.1.2 Cell proliferation and viability 
At 24 hours, 7 and 14 days, the Cell Proliferation Reagent WST-1 (Roche Diagnostics, GmbH, 
Mannheim, Germany) test was performed to assess cell proliferation and viability. WST-1 reagent 
contains tetrazolium salts that are cleaved to colored formazan by mitochondrial enzymes of cells 
(Berridge MV, et al., 1996). An expansion in the number of viable cells results in an increase in the 
overall activity of mitochondrial dehydrogenases in the sample. This augmentation in enzyme 
activity leads to an increase in the amount of formazan dye formed, which directly correlates to 
the number of metabolically active cells in the culture.  
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Briefly, 100 μl of WST-1 solution and 900 μl of medium (final dilution 1:10) were added to the cell 
monolayer, and the multi-well plates were incubated at 37°C for further 4 hours. Supernatants 
were quantified spectrophotometrically at 450 nm with a reference wavelength of 640 nm. Results 
of this test were reported as optical density (OD).  
8.1.3 Lactate dehydrogenase release (LDH) 
LDH reagent (Sigma Diagnostic, St Louis, MO) was used for the quantitative determination of LDH 
in the 24 hours supernatants. The reagent catalyzes the oxidation of lactate to pyruvate with 
simultaneous reduction of nicotinamide adenine dinucleotide (NADH) (Heffner J, et al., 1997). The 
formation of NADH results in an increase in absorbance measured at 340 nm. The rate of increase 
in absorbance is directly proportional to LDH activity in the sample. This test is a marker of 
cytotoxicity because only non-viable cells, with disrupted cellular membranes, release LDH. 
8.1.4 Bone-specific alkaline phosphatase activity (BAP) 
The skeletal, or bone-specific isoform of alkaline phosphatase is a tetrameric glycoprotein found 
on the cell surface of osteoblasts. BAP is an early differentiation marker of osteoblasts and it is 
involved in preparing the extracellular matrix for the ordered deposition of mineral component of 
bone (Price CP, 1993; Whyte MP, 1994). BAP immunoassay (Quidel Corporation, San Diego, CA, 
USA) was performed and provided a quantitative measure of BAP activity of MG63 cultured on 
both scaffolds and CTR. The concentration was evaluated at 405 nm in a microplate reader, using a 
standard curve.   
8.1.5 Osteocalcin measurements (OC) 
OC is found exclusively in bone tissue, is the most abundant noncollagenous protein of the 
extracellular bone matrix, is a highly-specific late osteoblast marker, and may be useful as a 
biochemical indicator of bone turnover.  
 88 
 
It is a 5800 molecular weight protein produced by osteoblasts; it contains three gamma-
carboxyglutamic acid residues that are thought to be involved in calcium ion and hydroxyapatite 
binding (Puchacz E, et al., 1989). The OC quantitative determination was assessed by the OC 
immunoassay (Quidel Corporation, San Diego, CA, USA) on collected supernatants. The OC 
concentration was evaluated at 405 nm in a microplate reader, using a standard curve.   
8.1.6 Type I pro-collagen production (CICP) 
Type I collagen is the primary organic constituent of bone: it forms about 90% of the organic 
material in bone matrix and bone hydroxyapatite crystals attach to the collagen fibrils in relation 
to the forces applied to bone. Its levels have been linked to bone growth and formation (Parfitt 
AM, et al., 1987-B). It is a triple-helical molecule, which forms the fibrous framework of all 
connective tissues and is synthesized as procollagen, a larger precursor molecule. Procollagen 
consists of mature collagen with extension peptides at both the amino and carboxy termini. These 
extension peptides, or propeptides, are cleaved from the collagen molecule by specific proteases 
prior to incorporation of collagen into a growing collagen fibril. The release of these peptides into 
the circulation provides a stechiometric representation of the production of collagen. Levels of 
CICP are indicative of collagen production in vivo. The determination of type I collagen production 
was based on the amount of CICP present in the cell supernatants and measured using a specific 
enzyme-linked immunoassay (Quidel Corporation, San Diego, CA, USA).  The concentration was 
evaluated in a microplate reader at 405 nm, using a standard curve.   
8.1.7 Transforming growth factor  β1 release (TGF-β1) 
TGF-β1, a member of the bone morphogenetic protein superfamily, is synthesized, with only few 
exceptions, by virtually all cells, enhances the deposition of extracellular matrix through 
promotion of synthesis and inhibition of degradation.  
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It plays critical roles in growth regulation and development, inhibits proliferation of most cells, but 
can stimulate the growth of some mesenchymal cells and can exert immunosuppressive effects. 
Moreover, it is inhibitive to T-and B- cell proliferation as well as to maturation and activation of 
macrophages, inhibits activity of natural killer cells and lymphokine activated killer cells and blocks 
production of cytokines. In the bone tissue, TGF-β1 is reported to increase preosteoblastic cell 
proliferation, to promote osteoblast differentiation and to stimulate extracellular matrix 
production (Barnes GL, et al., 1999). TGF-β1 was measured using the assay (Quantikine Human 
TGF-β1, R&D Systems, CA, USA) in cell culture supernatant by employing a quantitative sandwich 
enzyme immunoassay technique. The concentration was evaluated at 450/540 nm in a microplate 
reader, using a standard curve.   
8.1.8 Tumor necrosis factor α release (TNF-α) 
It is a polypeptide cytokine, produced by monocytes and macrophages and it acts as a multipotent 
modulator of immune response and further as a potent pyrogen. TNF-α activates neutrophils, 
altering the properties of vascular endothelial cells, regulating metabolic activities of other tissues, 
as well as exhibiting tumoricidal activity. Its production is mediated by the action of lymphokines 
and endotoxins on the macrophage and it may play a significant role in the pathogenesis of 
inflammatory disease of the joints and other tissues.  It is a pleiotropic cytokine that plays a 
central role in inflammation and apoptosis. It is reported that TNF-α promotes inflammatory cell 
infiltration, serves as chemotactic agent for monocytes and activates phagocytic mechanisms 
(MacEwan DJ, 2002). TNF-α regulates, also, the differentiation of hematopoietic stem and 
progenitor cells: in bone tissue, it induces bone resorption by stimulating the production of 
osteoclasts and by increasing the bone-resorbing activity of formed osteoclasts.  
 90 
 
A quantitative sandwich enzyme immunoassay against human TNF-α (R&D Systems, CA, USA) was 
performed and its concentration was evaluated at 450/540 nm in a microplate reader, using a 
standard curve.   
8.1.9 Interleukin 6 release (IL-6) 
While a number of interleukins are seemingly pleiotrophic in their effects, IL-6 may be considered 
the prototypic pleiotrophic cytokine. It is a variably glycosylated, 22-27 kDa secreted glycoprotein 
that serves as a prototype for a family of molecules that includes leukemia inhibitory factor (LIF), 
oncostatin M (OSM), ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-1) and IL-11. Cells, 
known to express IL-6, include CD8+ T cells, fibroblasts, synoviocytes, adipocytes, osteoblasts, 
megakaryocytes, endhotelial cells, sympathetic neurons, cerebral cortex neurons, cromaffin cells 
of the adrenal medulla, retinal pigment cells, mast cells, keratinocytes, Langerhans cells, fetal and 
adult astrocytes, neuthophils, monocytes, eosinophils, colonic epithelial cells, B1 B cells, and 
pancreatic islet beta cells (Kishimoto T, et al., 1995). IL-6 production is generally correlated with 
cell activation and it can be found in the blood of normal individuals in the 1 pg/ml range, with 
modest elevations in certain cancers (melanoma) (10 pg/ml), and large elevations after surgery 
(30-430 pg/ml). IL-6 has been described as a pro-inflammatory molecule, a modulator of bone 
resorption, a promoter of hematopoiesis, and an inducer of plasma cell development. It also has 
been shown to influence IL-4 production. The various activities of IL-6 suggest that this factor will 
have a major role in the mediation of the inflammatory and immune responses initiated by 
infection or injury. Particularly, it is considered a marker of the low tolerance of a biomaterial both 
in vitro and in vivo and is a modulator of bone resorption.  It was measured using the assay 
(Human IL-6 Immunoassay kit, R&D Systems, CA, USA) in cell supernatant by employing the 
 91 
 
quantitative sandwich enzyme immunoassay technique. The concentration was evaluated at 
450/540 nm in a microplate reader, using a standard curve.   
8.1.10 Total protein quantification 
The method of Lowry has been, for decades, the procedure of choice for quantification of soluble 
proteins due to its sensitivity, simplicity and precision. The procedure, used in this thesis, was 
based on Peterson’s modification of the micro Lowry method and used sodium dodecylsulfate, to 
facilitate the dissolution of relatively insoluble lipoproteins. The procedure is based on two 
chemical reactions. The first is the biuret reaction, in which the alkaline cupric tartrate reagent 
complexes with the peptide bonds of the protein. This is followed by the reduction of the Folin & 
Ciocalteu’s phenol reagent, which yields a purple color (Peterson GL, 1977). Absorbance of the 
colored solution was red at a suitable wavelength between 500 nm and 800 nm.  
 
8.2 STATISTICAL ANALYSIS 
Statistical evaluation of data was performed using the software package SPSS/PC+ Statistics TM 10.1 
(SPSS Inc., Chicago, IL USA). Data are reported as mean ± standard deviations (SD) of triplicate at a 
significance level of p<0.05. After having verified normal distribution and homogeneity of variance, 
a one-way ANOVA was done for comparison between groups. The Scheffé’s post hoc multiple 
comparison tests were performed to detect significant differences between groups. 
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8.3 RESULTS 
8.3.1 Cell adhesion and morphology 
-The results of adhesion, for MG63 cells, grown on tested materials, are summarized in Table 10. 
MG63 adhesion, after 4 h of incubation, on PCL and PCL/HA was normalized to that of CTR (100%), 
and no significant differences were found among the two scaffolds.  
Tab.10. Results of MG63 adhesion on PCL and PCL/HA (n=3). Results are reported as mean ± standard deviation (SD).  
MATERIAL ADHESION 
PCL 85 ± 2.3% 
PCL/HA 89 ± 3.0% 
 
-The cells, grown on both scaffolds, appeared well stained with a normal morphology (0 degree) as 
cells of control group. The cells appeared spindly with well defined cellular membranes and 
without lysis or reduced proliferation, in comparison to the control (Figures 27).  
a  b  
c  d  
e   f  
Fig.27. Neutral red staining. a, c, e magnification 10x; b, d, f magnification 4x. MG63 a, b) seeded on PCL;  c, d) seeded 
on  PCL/HA and e, f) in empty wells (control). (Images from Laboratory of Preclinical and Surgical Studies-IOR). 
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8.3.2 Cell proliferation and viability 
In Figure 28, the WST-1 viability test highlighted that cells, seeded onto the two scaffolds, at 24 
hours, proliferated well as control, without significant differences. At 7 days cells, on PCL/HA 
scaffold, proliferated significantly less than on PCL and control (CTR); at 14 days differences of 
viability between the two scaffolds were not observed, while cells grew significantly less on both 
two scaffolds than in empty wells (CTR). Moreover, cells seeded on both materials and CTR 
significantly increased proliferation between 24 hours and 7 days, while not between 7 and 14 
days. 
 
 
 
Fig.28. At 24 hours, no significant differences among materials and control were observed. 
At 7 days, *** p<0.0005: CTR Vs PCL/HA;  *p<0.05: PCL Vs PCL/HA. At 14 days, *p<0.05: CTR Vs PCL/HA and PCL. 
°°p<0.005: 7 days Vs 24 hours (PCL); °°°p<0.0005: 7 days Vs 24 hours (PCL/HA and CTR). 
 
 
 
 
 
 
 
 
 
 94 
 
8.3.3 Lactate dehydrogenase release (LDH) 
LDH release did not show significant differences among the two scaffolds and control (Figure 29). 
 
Fig.29.  No significant differences were observed among the scaffolds and control. 
 
 
8.3.4 Bone-specific alkaline phosphatase activity (BAP) 
As far as the differentiation markers were concerned, BAP values (Figure 30), an early marker of 
osteoblast differentiation, were significantly higher at 7 days for PCL/HA as compared to PCL and 
control, while at 14 days, for  PCL/HA as compared only to control. No significant differences were 
observed between the two experimental times. 
  
Fig.30. At 7 days, *p<0.05: PCL/HA Vs CTR and PCL. At 14 days, *p<0.05: PCL/HA Vs CTR. No significant differences 
between the two experimental times were observed. 
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8.3.5 Osteocalcin measurements (OC) 
The levels of OC, a late marker of osteoblast differentiation, were significantly higher only on 
PCL/HA as compared to PCL, at 7 days. Moreover, its production significantly increased on both 
scaffolds and control between 7 and 14 days (Figure 31). 
 
Fig.31. At 7 days, **p<0.005: PCL/HA Vs PCL. °p<0.05:14 days Vs 7 days (CTR); °°p<0.005:14 days Vs 7 days (PCL and 
PCL/HA). 
 
8.3.6 Type I pro-collagen production (CICP) 
In the CICP secretion (Figure 32), it could be observed that, at 7 days, cells seeded on PCL/HA 
scaffold produced significantly higher value than on PCL. No significant differences were observed 
among scaffolds and control at 14 days and between 7 and 14 days for all the scaffolds and 
control.  
 
Fig.32. At 7 days, *p<0.05: PCL/HA Vs PCL. No significant differences were observed at 14 days and between the two 
experimental times.  
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8.3.7 Transforming growth factor β1 release (TGF-β1) 
As observed in Figure 33, cells cultivated on both scaffolds and control at both experimental times 
produced TGF-β1 without significant differences. Moreover no significant differences were noted 
between the experimental times for all the scaffolds. 
 
Fig.33. No significant differences were observed among the two scaffolds and control, at 7 and 14 days,  and between 
the two experimental times. 
 
8.3.8 Tumor necrosis factor α release (TNF-α) 
TNF-α levels showed no significant differences among scaffolds and control at 7 and 14 days. 
Moreover, its production, on PCL/HA, was significantly lower at 14 days as compared to that at 7 
days (Figure 34). 
 
 
Fig.34. No significant differences were observed among the two scaffolds and control at 7 and 14 days. °p<0.05: 7 days 
Vs 14 days (PCL/HA). 
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8.3.9 Interleukin 6 release (IL-6) 
No significant differences were observed among scaffolds and control at 7 and 14 days and 
between the 2 experimental times (Figure 35). 
 
 
Fig.35. No significant differences were observed among the two scaffolds and control at 7 and 14 days and between 
the two experimental times.  
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9. IN VIVO STUDY 
A biological response to a scaffold, implanted in a human host, is characterized by physiological 
effects from surgery trauma, the presence of the implant, the subsequent inflammatory reaction 
and the remodeling of the nearly tissue. All these factors might be evaluated by in vivo animal 
models, because the pre-clinical efficacy of every innovative therapies, based on the implant of 
bioactive or engineered materials, requires a preclinical evaluation (Fini M, et al., 2006).  
This phase is performed according to European and Italian legislation on animal experimentation: 
Law by Decree January 27, 1992, No.116. and the ethical principles state in the “Guide for the Care 
and Use of Laboratory Animals”. Briefly, in this thesis, the experimental animal protocol was sent 
and approved by the Scientific Ethical Committee, responsible public authorities of Rizzoli 
Orthopaedic Institute and the Italian Ministry of Health. Following laws on animal 
experimentation, animals were acquired from authorized farms, submitted to a quarantine period 
(10 days) before the utilization and to a standard and controlled diet. All surgical procedures were 
performed under general anaesthesia, with the control of animal welfare by a veterinarian and 
with post-operative analgesic therapy in  order to avoid pain and suffering. In order to reduce the 
species variability, a sufficient number of animals per group, homogeneous for sex, age, nutrition 
and environment, was chosen (Buma P, et al., 2004).  
 
 
 
 
 
 99 
 
9.1 MATERIALS AND METHODS 
Fourteen skeletally mature, adult male New Zealand rabbits (Charles River, Calco, Lecco, Italy), 
with a body weight of 2.7 ± 0.3 Kg, were housed under controlled conditions (room temperature 
22±0.5 °C; relative humidity 55±5%; 12 h of light and 12 h of darkness) and were supplied with 
standard diets and water ad libitum. At time of surgery, a general anaesthesia was induced with an 
intramuscular injection of 44 mg/kg Ketamine (Imalgene 1000, Merial Italia S.p.A, Assago-Milano, 
Italy) and 3 mg/kg Xylazine (Rompun Bayer AG, Leverkusen, Germany), and assisted ventilation 
(O2:1 l/min; Air: 0.4 l/min; Sevorane: 2.5–3%). In sterilized conditions, after shaving, disinfection 
and sterile draping of the operation site, a 2-cm skin incision was made on the lateral aspect of 
distal femoral condyles of both legs. Bilateral confined cancellous defects were drilled in both 
limbs with a growing diameter drill (from 3.2 mm to 5 mm in diameter), obtaining a defect with 5 
mm in diameter and 10 mm in depth (Figures 36). All the defects were carefully rinsed with 
Ringer’s solution and cleaned out, so that any abraded particles, formed during drilling, were 
removed. 
In all fourteen rabbits, the left defect was treated with PCL/HA scaffold, while the right one with 
PCL (cylinders of 5 mm in diameter and 10 mm in height). Seven rabbits were euthanized after 4 
weeks (Group 1) and the others after 12 weeks (Group 2). Eleven and four days before euthanasia, 
the animals received two intramuscular injections of oxytetracycline (30 mg/Kg). This antibiotic 
bounds selectively to new-formed bone tissue and is visible with fluorescence techniques. At the 
end of the experimental times, under general anaesthesia, the animals were pharmacologically 
euthanized with intravenous injection of 1 ml Tanax (Hoechst AG, Frankfurt-am-Mein, Germany). 
Femurs were removed, stripped of soft tissues and, after macroscopic observation, were 
processed for histological and histomorphometric evaluations.  
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Fig.36. A: skin incision; B-C-D-E: utilize of drills with growing diameters to obtain a bone defect of 5 mm in diameter 
and 10±0.5 mm in depth. (Images from Laboratory of Preclinical and Surgical Studies-IOR). 
 
9.1.1 Histology and histomorphometry 
The femoral condyles of rabbits were fixed in 4% para-formaldehyde for 48 h for undecalcified 
bone processing; the samples were then dehydrated in graded series of alcohols for 24h, 
respectively (50°, 75°, 95° twice and 100° twice). After a 24h-infiltration period in 
methylmetacrilate, they were finally embedded in poly-methylmetacrilate (Merck, Schuchardt, 
Hohenbrunn, Germany). Femur blocks were sectioned along a plane parallel to the longitudinal 
axis of femour with Leica 1600 diamond saw microtome (Leica SpA, Milan, Italy), obtaining a series 
of sections of 100±10 µm in thickness.  
Subsequently these sections were thinned and polished  (Struers Dap-7, Struers Tech, Denmark) to 
a thickness of 30 ± 10 μm.  
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Histology and Static histomorphometry 
A total of three consecutive sections for each sample were obtained, stained with Toluidine blue, 
Acid fuchsin and Fast Green and analyzed for histological and histomorphometric evaluations. 
Toluidine Blue is a basic stain, that bounds to electrically negative structures (nucleic acid) and 
especially to glycosaminoglycans and proteoglycans (cartilage fundamental substance), making 
cartilage blue. Fast green contains acrylic groups, bounding to bone structure, making this tissue 
green. Acid fuchsin is an organic stain, used in association with the other stains. All of them, 
combined, represent the routine staining for the bone and cartilage tissues. Histological and 
histomorphometric analyses were performed by means of a light optic Olympus BX41 microscope 
(Olympus Italia Srl, Milano, Italy) at different magnifications and the QWIN image analysis 
software (Leica Imaging Systems Ltd, Cambridge; England). Histological evaluation was performed 
at different magnifications (1.25x, 2x, 20x and 40x). 
For static histomorphometry, three parameters were evaluated:  
-  BONE HEALING RATE (BHR, %): represents the healing of the bone defect in terms of decrease 
of its area. It was calculated by the ratio of decreased bone defect area, after scaffolds 
implantation, with the initial area of the defect (initial defect area=19,6 mm²) expressed as 
percentage. For BHR evaluations, the area of the defect was manually measured with Leica 
QWIN software at 1.25x of magnification. 
-  BONE AREA: the new bone was measured outside (BAr/TAr) and inside (BAr/TArint) the 
implanted scaffolds and it was expressed as percentage of newly formed bone divided by the 
area of the entire analyzed region. Briefly, 4 region of interests (ROIs), at 20x of magnification, 
were selected to cover the entire condyle defect. The ROIs were binarized, by means of the 
Leica QWIN software.  
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Dynamic histomorphometry 
Subsequently, other 3 sections for each specimen were observed with fluorescent microscopy 
(Olympus Italia Srl, Milano, Italy) at 20x of magnification and the following parameters were 
calculated:  
- MINERAL APPOSITION RATE (MAR, μm/day): the rate of progression of the mineralization 
front labeled twice as index of osteoblast activity. It was calculated with the following 
equation: 
4



t
n
x
MAR  
Σx= sum of all the measurements between double labels, π/4= the obliquity correction factor, 
n=(10) the total number of measurements and t= the time interval of the oxytetracycline 
administration (7 days). The measurement is the distance between two parallel fluorescent 
labeled trabecolae (Giavaresi G, et al., 2010).  
- BONE FORMATION RATE (BFR/B.Pm or BFR) (μm2/μm/day): the quantity of mineralized bone 
expressed per unit of bone perimeter per day. This value is calculated as: 
BFR= MAR*(1/2 sL.Pm/B.Pm+dL.Pm/B.Pm). 
sL.Pm= perimeter of single labeled trabecolae, B.Pm=perimeter of trabecolae; dL.Pm= perimeter 
of double labeled trabecolae (Giavaresi G, et al., 2010). 
9.2 STATISTICAL ANALYSIS 
Statistical evaluation of data was performed by using SPSS v12.1 software (SPSS Inc.). Data are 
reported as Mean±SD at a significant level of p<0.05. Two-way (scaffold, experimental time) 
ANOVA, followed by Bonferroni’s t test, was applied to compare histomorphometric data.   
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9.3 RESULTS 
9.3.1 Histology and histomorphometry 
Histological evaluations at 4 weeks, revealed an initial presence of thin, new bone trabeculae from 
preexistent  bone, that progressively occupied the peripheral zones of the defect (Figures 37 a, b), 
till 12 weeks, when the new bone was formed inside the porosity, also in the central portion of the 
both scaffolds (Figure 37 c). New bone trabeculae were recognized because are thin than the 
preexistent old bone and were present inside and outside the scaffolds (Figures 37 a, b, c). At 12 
weeks, for all the scaffolds, the new bone trabeculae, outside the scaffolds, appeared more dense 
than at 4 weeks, that instead were thin and rarefied, as observed in Figure 37 b, c. Inside the outer 
new trabeculae, it was revealed the presence of lacunae with osteocytes and osteoblasts along the 
perimeter (intense blue staining) (Figure 37 c). In the peripheral parts of the implanted scaffolds 
numerous fibroblasts, fundamental cells of connective tissue with their fusiform aspect, few 
macrophages and few leukocytes were observed (Figure 37 d) and no fibrous capsule, between 
the scaffolds and outer bone, was noted for both scaffolds at both experimental times (Figures 
37). Moreover, at 12 weeks the new bone was more than at 4 weeks, especially in case of PCL/HA. 
Figure 38 clarifies the presence of new bone trabeculae inside the scaffolds at 12 weeks, where 
the material was still visible and it was only partially degraded.  
 Figures 39 show images of the two scaffolds at the two experimental times at 1,25x of 
magnification and confirm the above mentioned observations.   
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a                                              b  
c     d  
Fig.37. a) PCL and b) PCL/HA initial trabeculae invasion, observed in the peripheral zones of the implanted materials, 
at 4 weeks. c) PCL/HA at 12 weeks with increasing trabeculae inside the scaffold and lacunae with osteocytes within 
the outer new trabeculae, that have an higher thickness in comparison to those at 4 weeks. d) Fibroblasts (FB), few 
macrophages (M) and few leukocytes (L) are observed in the peripheral part of  the implanted material. The scaffolds 
are still present after 4 and 12 weeks. a), b) and c) Magnification 20x; d) Magnification 50x. M= materials; L= lacunae; 
TT= trabeculae thickness of outer bone; BT= new bone trabeculae inside the scaffolds. Toluidine blue, Acid fuchsin and 
Fast Green staining. 
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a  b  
Fig.38. PCL/HA at 12 weeks. a)  Magnification 4x,  b) magnification 20x. M= grey material; BT= blue new bone 
trabeculae. Toluidine blue, Acid fuchsin and Fast Green staining. 
 
 
a) PCL/HA 4 weeks 
 
b) PCL/HA 12 weeks 
 
c) PCL 4 weeks 
 
d) PCL 12 weeks 
 
Fig.39. PCL and PCL/HA at 4 and 12 weeks. a), b) PCL/HA; c), d) PCL. a), c)  4 weeks; b), d) 12 weeks. Magnification 
1,25x. M= material; NB= new bone trabeculae; PB= preexistent bone. The new bone is recognized because thinner 
than the preexistent old bone. Toluidine blue, Acid fuchsin and Fast Green staining. 
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The values of BHR, BAr/TAr and BAr/TArint, expressed as percentage, are summarized in Table 11. 
As BHR values are concerned, significant differences, between the two scaffolds and the two 
experimental times, were not observed. It was noted that the defect is reduced nearly of 40-50% 
within 4 weeks and it was maintained till 12 weeks (Figure 40 a). 
BAr/TAr showed significantly higher value with of PCL/HA than with PCL at 12 weeks. At 12 weeks, 
for each scaffolds, significantly higher values were observed than at 4 weeks (Figure 40 b). 
BAr/TArint was significantly higher with PCL/HA than PCL at both experimental times, moreover an 
improvement of this parameter was observed, for each scaffolds, at 12 weeks in comparison to 4 
weeks (Figure 40 c). 
As observed in figures 41 a) and b) and in Table 11, MAR values, at 4 and 12 weeks, were 
significantly higher with PCL/HA scaffolds in comparison to PCL scaffold. The values were also 
significantly higher at 12 weeks for both scaffolds in comparison to those at 4 weeks. The same 
trend, observed for MAR, was found also for BFR value. In Figure 42, an example of fluorescent 
sections for the evaluation of MAR and BFR is reported. 
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a    
b  
c  
Fig.40. a) BHR: No differences were observed between the two materials at 4 and 12 weeks and between the two 
experimental times. b) BAr/TAr (%):*p < 0.05: PCL/HA Vs PCL at 12 wks; °°° p <0.0005: 12 wks Vs 4 wks for each 
scaffolds.  At 4 weeks no differences are observed between the scaffolds. c) BAr/TArint (%):***p<0.0005: PCL/HA Vs 
PCL at 4 and 12 wks; °°° p < 0.0005: 12 wks Vs 4 wks for all scaffolds.  
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a  
b  
Fig.41. a) MAR (μm/day): ** p<0.005: PCL/HA Vs PCL at 4 wks; *** p<0.0005: PCL/HA Vs PCL at 12 wks;  °° p<0.005: 12 
wks Vs 4 wks for PCL; °°° p<0.0005: 12 wks Vs 4 wks for PCL/HA; b) BFR (μm
2
/μm/day): ** p<0.005: PCL/HA Vs PCL at 4 
wks; *** p<0.0005: PCL/HA Vs PCL at 12 wks; °° p<0.005: 12 wks Vs 4 wks for PCL; °°° p<0.0005: 12 wks Vs 4 wks for 
PCL/HA. 
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a   b  
Fig.42. Examples of fluorescent sections for dynamic histomorphometry, at 4 weeks. Magnification 20x. a)PCL and b) 
PCL/HA. NB=New bone trabeculae, labelled with oxytetracycline; M= materials.  
 
 
Tab.11. Results of static and dynamic histomorphometry and relative statistical analyses. 
SCAFFOLD EXPERIMENTAL 
TIME 
BHR  
(%) 
BAr/TAr 
(%) 
BAr/TArint 
(%) 
MAR 
(μm/day) 
BFR 
(μm
2
/μm/day) 
PCL 4 wks 47.5 ± 1.9  20.9 ± 5.3 0.2 ± 0.1 2.2 ± 0.4 352.5 ± 24.7 
PCL 12 wks 53.8 ± 5.4  34.2 ± 1.9°°° 3.9 ± 0.9°°° 3.1 ± 0.6°° 401.4 ± 140.0°° 
PCL/HA 4 wks 43.7 ± 1.3  21.2 ± 2.7 0.9 ± 0.4*** 2.7 ± 0.1** 362.4 ± 21.1** 
PCL/HA 12 wks 54.5 ± 5.4  40.8 ± 3.6*,°°° 8.2 ± 0.2***,°°° 4.6 ± 0.4***,°°° 699.2 ± 173.3 ***,°°° 
 
- BAr/TAr (%):*p<0.05:PCL/HA Vs PCL at 12 wks; °°° p<0.0005:12 wks Vs 4 wks for each scaffolds. 
- BAr/TArint (%):***p<0.0005:PCL/HA Vs PCL at 4 and 12 wks; °°° p<0.0005:12 wks Vs 4 wks for all scaffolds. 
- MAR (μm/day): ** p<0.005:PCL/HA Vs PCL at 4 wks; *** p<0.0005:PCL/HA Vs PCL at 12 wks; 
             °° p<0.005:12 wks Vs 4 wks for PCL; °°° p<0.0005:12 wks Vs 4 wks for PCL/HA. 
- BFR (μm
2
/μm/day): ** p<0.005:PCL/HA Vs PCL at 4 wks; *** p<0.0005:PCL/HA Vs PCL at 12 wks;  
              °° p<0.005:12 wks Vs 4 wks for PCL; °°° p<0.0005:12 wks Vs 4 wks for PCL/HA. 
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10. DISCUSSION AND CONCLUSIONS 
In this thesis, PCL scaffold, with a well-controlled microarchitecture, was manufactured by the 
combination of gas foaming (GF) and selective polymer extraction (PE) from co-continuos blends 
technique. Gas-foaming based technique has emerged as very promising tool for the design of 
porous synthetic scaffolds with finely controlled biochemical and biophysical properties; this 
approach avoids the use of organic solvents, potentially harmful to cells and tissues. In literature, 
GF and PE techniques were selected and combined to regulate scaffold morphology on a single or 
double scale (Harris DL, et al., 1998; Sarazin P, et al., 2004; Salerno A, et al., 2007; Kanczler JM, et 
al., 2008). The appropriate selection of blend composition and GF process parameters allows the 
design of highly interconnected porous network of PCL scaffolds suitable to be used for tissue 
engineering. In this thesis, the microstructural parameters have been designed by selecting a 3/2 
(w/w) PLC/TG and optimizing the GF processing conditions. Consequently, the final μ-bimodal PCL 
scaffold prepared was characterized by high interconnectivity and good mechanical responses, 
with porosity uniformly distributed between the macroporosity, created by the selective 
extraction of the TG, and the microporosity, induced by the GF process (Salerno A, et al., 2008). 
Slow degrading PCL has attracted much interest since its first appearance as bone substitute and 
has been extensively tested as film, 3D, and nanofibrous scaffold, and for drug delivery, but these 
products are limited in inducing a regenerative response from bone cells, once implanted. It has 
been demonstrated that the incorporation of biocompatible insoluble signals, such as 
hydroxyapatite (HA), into polymer matrix, promotes cell activity, due to the well-known 
osteoconductive and osteogenic potential, as well as an improvement of mechanical properties for 
its reinforcement action. The idea of combining bioactive ceramics and degradable polymers to 
produce 3D scaffolds with high porosity is a promising strategy for the design and development of 
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composite system for hard tissue regeneration materials (Taddei P, et al., 2005; Koh YH, et al., 
2006; Guarino V and Ambrosio L, 2008).  
In this thesis, for the fabrication of composite PCL/HA scaffold, among several processing 
techniques to achieve a highly porous structure (i.e solvent casting, phase inversion, fiber bonding, 
melt based technologies, high pressure based methods, freeze drying), the phase 
inversion/particulate leaching technique has been chosen. This procedure of preparation involves 
the precipitation of a polymer solution in which salt particles are dispersed and the subsequent 
leaching out of the salt (Guarino V, et al., 2008). Moreover, this technique enables the 
incorporation of HA solid signals without relevant complications during the preparation 
procedure, using solvents that do not alter the osteoconductive potential of the HA filler. A highly 
controlled porosity, characterized by a bimodal distribution of pore size, was achieved: an open 
macroporous network that assures a uniform cell distribution and tissue regeneration, appeared 
interconnected by micropores that provide an efficient transport of soluble signaling molecules, as 
well as nutrients and oxygen, and metabolic waste removal. 
For the bony ingrowth into a scaffold, it has been shown that the interconnected pores are 
important to induce mineralized bony tissue to form inside the macropores of scaffolds. Scaffolds 
characterized by pores with mean diameters ranging from 100 to 500 µm (macroporosity) and 
pores with diameters of few microns (microporosity) may provide suitable 3D substrates for both 
cell colonization/biosynthesis and fluid transport. Apart from pore size, other important variables 
in orthopaedic applications, related to the scaffold physical features, are the percentage of 
porosity and the interconnectivity of the pores. Klawitter and coworkers showed that the potential 
for bone ingrowth was found with a range of pore diameter between 40-100 µm. It has been 
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reported that the pore interconnection is important for angiogenesis and osteogenesis inside the 
scaffold by improving the fluid flow and nutrient supply (Klawitter JJ and Hulbert SF, 1971).  
There are different methods to evaluate the porosity and interconnectivity of a scaffold and the 
most suitable techniques are represented by water immersion, mercury intrusion porosimetry, 
SEM and Image analysis and all of them show some drawbacks.  
Water immersion is a method that only provides information on the empty space within the 
material. The porosity or empty space, measured by this method, includes all the micropores as 
well as macropores. This method is not able to provide objective and quantitative information 
about pore size and pore interconnection. Mercury porosimeter is based on the physical principle 
that a nonwetting liquid does not penetrate fine pore until sufficient pressure is applied. The 
required pressure is inversely proportional to the size of the pores according to the Washburn 
equation with the assumption that the pore is cylindrical and well connected. Therefore, the pore 
size distribution, obtained from mercury porosimeter, does not represent pore diameters but 
instead a measurement more closely related to the size of the interconnections between pores. 
The mercury porosimetry only provides partial information on the entire porous structure. SEM is 
a very useful method to demonstrate the micropore structure. However, the quantification of the 
pore structure is dependent on the image analysis of 2D images obtained from the scan, but the 
network of the pore structure is in a 3D manner, which required a 3D method to analyze it (Hiu-
Yan Y, et al., 2005). It is evident, that all the previous techniques, used for the study of a material 
porosity, alone are not complete and can give different results because they analyze different 
aspects of porosity. Therefore, an alternative is required to provide more comprehensive 
information on the physical distribution, size, and connectivity of the pores within the porous 
scaffolds in a 3D space. Unlike the water immersion and SEM techniques, the Micro-CT is a 
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method that provides information on functional porosity and 3D interconnection apart from 
delivering a detailed report on parameters of the material structure objectively. The porosity of 
the scaffolds, measured by Micro-CT, can be calculated based on the void volume of scaffolds. 
With Micro-CT, the porosity is calculated from the 2D images by the percentage of void area 
within the porous material area, while for 3D structural evaluation, the volume of interest is 
reconstructed (Intranuovo F, et al., 2011). Micro-CT seems to be the most complete method to 
study all the porosity parameters in 2D and 3D manners (Engelke   K, et al., 1993; Muller  R, et al., 
1998; Schmidt C, et al., 2003).  
In this thesis, the overall porosity, microporosity, macroporosity percentages, at rest and after 
mechanical compression, were evaluated with Micro-CT technique, underling that PCL/HA scaffold 
showed higher overall porosity and macroporosity in comparison to PCL and that both scaffolds 
possessed a good interconnectivity of nearly 99%. The pore size evaluations revealed that PCL 
scaffold had the maximum pore size of about 500 µm and the minimum of about 7 µm or few. On 
the other hand, PCL/HA had pores size that reached dimensions of 900 µm, even if they are very 
few. For both scaffolds, pores with few microns of dimension were more than larger pores and 
after compression steps the number of micropores increased. 
Moreover, according to the Micro-CT capability to study 2D and 3D structure of an internal object 
without sample preparation, Micro-CT could be considered very useful to observe cell behaviour 
inside a scaffold. Indeed cells, scaffolds and growth factors are combined in the in vitro phase, 
which is a crucial moment for the successful outcome of applied tissue engineering scaffold. The 
need to display the architecture of materials and especially the cellular distribution inside the 
constructs has consequently triggered different technical efforts to reach this aim. The most 
common method for examining cells in scaffolds is still microscopy, based on embedding the 
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sample, sectioning and finally histological staining. Clearly, this technique is destructive and only 
semi-quantitative. For this approach, fluorescence microscopy can provide a quantitative 
evaluation, but combined with a confocal equipment to obtain 3D images. However, the analyzed 
depth is very limited and the interior of opaque materials is still a drawback for a complete 
imaging (Dorsay SM, et al., 2009). In this thesis, to obtain analytical images, back-scattered 
electrons (BSE), used by SEM technique, highlighted how the interaction, between osmium and an 
electron beam, generated a light image of the cells. The same concept was applied to the Micro-CT 
technique, where the lighter the pixel in Micro-CT sections was, the higher the voxel’s absorption 
was, to observe the cell colonization inside the scaffold analytically. The evident overlap of surface 
images, obtained by these alternative ways, showed that this new method is a reliable tool for cell 
visualization. Although currently the most widely used technique to observe the material surface 
colonization is electron microscopy, these results highlighted the usefulness of SEM to investigate 
the external coating of the construct, and also the validity of Micro-CT. Thus, SEM and Micro-CT 
might be two complementary approaches aimed for evaluation of an engineered construct over 
time from different points of view: SEM is useful to investigate the material surface, whereas 
Micro-CT allows the scaffold to be assessed three-dimensionally in terms of cell colonization and 
increasing material degradation rate (Chen Y, et al., 2011). To date, only few studies analyzed the 
cellular compartment in constructs or soft tissues by Micro-CT (Dorsay SM, et al., 2009; Intranuovo 
F, et al., 2011; Zehbe R, et al., 2010; Metsher BD, 2009; Chen Y, et al., 2011): in the future it would 
be very interesting to apply this “microscale” technology for tissue engineering to evaluate the 
scaffold and to predict a clinical outcome. In this project, a method was established to detect cells 
within the PCL scaffold to make correct statistical comparisons between samples. The nominal 
resolution used here (2.5 µm of pixel size) allowed the presence of cells to be detected, even in 
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Micro-CT sections far from the surface. The MG63 osteosarcoma cell line, used to assess the 
visualization technique, can grow in multilayers and continue to proliferate over time. Thus, this 
characteristic was used to ensure the presence of cell colonization even in deeper layers of the 
scaffold. The method, presented here, was developed after observing the X-ray attenuation 
histograms obtained. The method described is good for 3D quantification of cell distribution 
considering the intrinsic properties of Micro-CT analysis, indeed, due to its 3D analysis nature, 
Micro-CT allows the results obtained by qualitative surface analysis to be combined and gives a 
more complete understanding of cell colonization. By observing all images, both at 1 week and at 
2 weeks after seeding, the PCL appeared to be completely colonized by cells seeded at all the 
concentration used. A difference in the volume distribution was visible by composing 3D models of 
the analyzed samples. Indeed, in addition to increased cell volume at 2 weeks compared to 1 week 
after seeding, the cells with an initial concentration of 2x105 cells/cm2 showed a more uniform 
colonization of the PCL scaffold over time. Surface observations (for example by SEM) or 
observations of the most superficial layers alone might therefore not be sufficient for a correct 
correlation with quantitative biological data. In fact, quantitative analysis of the surface alone both 
by SEM and by Micro-CT showed fewer cells at both experimental times for the 2x105cells/cm2 
concentration, whereas quantitative analysis showed a more widespread internal colonization. A 
good cell infiltration capacity was observed within the PCL scaffold according to the topological 
properties of its pore structure. The results of this part of Micro-CT study suggest that not only 
scaffold porosity, but also the number, type and size of seeded cells, as well as the seeding 
technique are necessary to avoid an excessive and fast colonization of the scaffold periphery. The 
results could be of particular relevance also for applications of the scaffolds in in vitro tissue 
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engineering field where an engineered construct may be developed in laboratory for the 
subsequent implantation.  
For the subsequent in vitro biocompatibility assessment of the scaffolds, ISO 10993 Part 5 “Tests 
for in vitro cytotoxicity” lists three categories of tests: extract test, direct-contact test, indirect-
contact test, selected by the nature of the materials to be evaluated, the potential site of use and 
nature of their use. In the present study the direct-contact tests were chosen because the 
scaffolds were proposed as bone fillers, promoters of bone healing and as scaffolding materials for 
cell growth, thus they had to come in contact with bony tissue.  
Biological in vitro evaluations were performed at 24 hours, 7 and 14 days. An established cell line 
(MG63), due to its reproducibility, standardization and accuracy in understanding the response, 
was chosen (Fini M and Giardino R, 2003).  
As stated in the ISO 10993-5, after the culture period, the cytotoxic effects of tested materials on 
cells were evaluated by means of both qualitative and quantitative analyses. Measurements of cell 
adhesion, gave similar results, for both scaffolds and control, without significant differences, with 
a percentage of 85 and 89% for PCL and PCL/HA, respectively.  Analogies were also observed in the 
morphology of cells seeded in empty wells and in both scaffolds: after 24 hours of culture, the 
cells appeared spindly with well defined cellular membranes and without lysis or reduced 
proliferation. Moreover, LDH activity was comparable among tested materials and control, 
indicating an absence of cytotoxicity of both scaffolds. Cell proliferation tests, evaluated at 24 
hours, 7 and 14 days, underlined that cells grew regularly on materials and control: their 
proliferation significantly increased between 24 hours and 7 days and was maintained between 7 
and 14 days. In particular, at 7 days PCL/HA cells showed a lower proliferation than PCL and 
control cells, probably due to the starting of the differentiation process.  Indeed, at 7 days, PCL/HA 
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cells produced significantly higher level of BAP than PCL and control, and OC and CICP than PCL. At 
14 days, BAP was produced significantly more by cells on PCL/HA in comparison to control. The 
production of OC increased between 7 and 14 days in all materials and control, in significantly 
manner, underlying its role as a late differentiation marker of osteoblasts, whereas the production 
of BAP and CICP did not show significant differences among experimental times. As about TGF-β, 
TNF-α and IL-6 synthesis, no differences were observed nor among scaffolds and control at both 
experimental times, nor between 7 and 14 days. Moreover, the production of TNF-α, was 
significantly lower on PCL/HA at 14 days in comparison to 7 days.  
Thus, results of the in vitro study showed that the PCL and PCL/HA possessed a good in vitro 
biocompatibility. In fact the materials did not affect cell proliferation and did not evoke cytotoxic 
or inflammatory effects as explained by the TNF-α, IL-6, LDH production by the materials, that did 
not differ from control. Cells cultured on the scaffolds showed a good biofunctionality and 
bioactivity, as demonstrated by the amount of extracellular matrix components, at both 
experimental times. In particular, PCL/HA showed an early differentiation process, starting at 7 
days and maintaining up to 14 days, demonstrated by an enhanced production of BAP, OC and 
CICP than PCL, especially at 7 days. In conclusion PCL/HA revealed better biocompatibility and 
bioactivity when compared to PCL and control.  
Then, the in vivo evaluations were performed. ISO requires both in vitro and in vivo tests for a 
complete assessment of biocompatibility (ISO 10993-1. Guidance on selection of tests). As with 
any experimental investigation, and in animal testing, the validity of the experimental model for 
the researched question is of decisive importance for the evaluation of the test results. In order to 
be able to study the stimulating effect of various implanted materials on bone regeneration, 
investigations about the kinds of animal models have to be performed. Desirable attributes of an 
 118 
 
animal model include demonstration of similarities with humans, both in terms of physiological 
and pathological considerations, as well as being able to observe numerous subjects over a 
relatively short time frame (Pearce AI, et al., 2007). When deciding on the species of animal, there 
are several factors that should be considered. One must define clearly the research question being 
addressed, prior to selecting the species of animal to be used in the study. Animal selection factors 
include: cost to acquire and care for animals, availability,  acceptability to society, tolerance to 
captivity and ease of housing. In the last decades a suitable animal model was investigated to 
study bone repair mechanisms. Among different models, rabbit has several advantages, such as 
standardization of the experimental conditions, easier housing and experiment repeatability, low 
cost and high bone turnover rate, proponing rabbit as one of the  preferred test animal for the in 
vivo step of the present thesis. Moreover, rabbits are very commonly used as model of bone 
healing and the efficacy of osteoinductive agents and osteoconductive scaffolds. The rabbit is also 
convenient in that, because it reaches skeletal maturity shortly after sexual maturity at around 6 
months of age (Pearce AI, et al., 2007).  
The in vivo tests were performed, comparing, with qualitative (histology) and quantitative (static 
and dynamic histomorphometry) analyses, the behaviour of the two scaffolds, in terms of bone 
healing defect, new bone formation inside bone defect and porous scaffold and of animal 
tolerability, after their implantation in a rabbit femoral condyle defect. An important aspect of the 
histomorphometry is represented by the dynamic parameters MAR and BFR. Histomorphometry 
or quantitative histology is the analysis on histological sections of bone resorption, formation and 
structure parameters and it is the only technique that allows a dynamic evaluation of the activity 
of bone modeling after labeling with tetracycline. Moreover, the new measurement procedures, 
through the use of the computer, allow an assessment of bone microarchitecture too. They are 
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employed in the evaluation of bone damage associated with particular treatments. As about 
dynamic histomorphometry, bone formation rate (BFR) represents the quantity of mineralized 
bone per trabecular perimeter per days. This parameter would reflect more frequent replacement 
of bone and would correspond to the higher values for both bone turnover and osteocytes 
density. The mineral apposition rate (MAR) is determined by dividing the mean distance between 
the oxytetracycline labels by the time interval between the administration of the two labels and it 
reflects the bone-forming capacity of osteoblasts at the bone multicellular unit (BMU) level 
(Schopper C, et al., 2009; Bloebaum RD, 2007; Giavaresi G, et al., 2010).  
Histology and the calculated histomorphometry parameters, evaluated after 4 and 12 weeks from 
the scaffold implantation, showed that new bone trabeculae started to be formed in the periphery 
of the scaffolds at 4 weeks, and then penetrate the porosity and internal structure of the scaffolds, 
at 12 weeks, especially for PCL/HA scaffold. Histological analysis evidenced the absence of a thick 
fibrous inflammatory capsule, without inflammatory cells around the implanted materials, 
underling that the scaffolds were well tolerated by the animals. It was observed that both 
materials were present at the end of the both experimental times and they were only partially 
degraded. 
The initial area of the defect was reduced of about 40-50%, after 4 weeks, without significant 
differences between the two materials and between the two experimental times, indicating that 
within 4 weeks the healing process started faster and then proceeded slower between 4 and 12 
weeks.  
The formation of new bone trabeculae outside the implanted materials (BAr/TAr) did not shown 
differences between the two scaffolds at 4 weeks, but at 12 weeks, PCL/HA had significantly 
higher values of BAr/TAr than PCL. Moreover, between 4 and 12 weeks, this value increased, with 
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the two scaffolds, in a significantly manner. The new bone trabeculae started to penetrate the 
porosity of the two scaffolds slowly, at 4 weeks, in the peripheral zones with values of BAr/TArint of 
about 0.2 and 0.9% for PCL and PCL/HA, respectively; at 12 weeks, this value was significantly 
higher than at 4 weeks, reaching a percentage of 3.9 and 8.2 for PCL and PCL/HA, respectively. 
Moreover, for each experimental times, PCL/HA showed significantly higher values of BAr/TArint in 
comparison to PCL.  
As about dynamic histomorphometry, MAR and BFR showed the same trend: at 4 and 12 weeks 
PCL/HA values were significantly higher than those of PCL and, between 4 and 12 weeks, MAR and 
BFR results significantly increased in the presence of both scaffolds.  
Through time, new bone formation increased outside more than inside the porous scaffold, 
especially for PCL/HA scaffold and the bone outside the scaffold become more dense between 4 
and 12 weeks.    
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11. ADVANTAGES, LIMITS AND FUTURE OF THE PROJECT 
This thesis has permitted the evaluation of different materials, polymeric and polymeric/ceramic 
scaffolds, proposed to be used as bone fillers in orthopaedic surgery, and described the most 
important steps, from the fabrication to the in vivo animal models passing through mechanical and 
in vitro tests, for the characterization of materials before their clinical use. The first steps of 
morphological and mechanical characterization of the scaffolds were evaluated in the laboratories 
in which the materials were performed. In the laboratory, where my thesis work was developed, 
the subsequent tests of Micro-CT evaluation of the scaffolds porosity at rest and after 
compression stages and in vitro and in vivo studies were done and underlined that both scaffolds 
are biocompatible, bioactive, biofunctional and well tolerated by cells, tissues and animals, with 
new bone trabeculae that started to grow inside the scaffold porous structure. Moreover, during 
these three years of PhD, a method for the visualization, distribution and quantification of cells 
inside the scaffolds was established. A limit of this research was represented by the lack of  a 
comparison with PCL/HA scaffold in terms of cell distribution, because this new method was 
tested only on PCL scaffold, and once established, in the future, it will be adopted for PCL/HA too. 
The results of cell-scaffold interaction study demonstrated that high cell seeding efficiency and 3D 
colonization may be achieved by fine tuning the topological characteristics of the scaffold. In 
particular, the μ-bimodal scaffolds promoted selective 3D cell colonization into the macroporosity, 
and consequently ensured the presence of a separate porous network for fluid transport.  
Due to the low degradation feature of PCL material, only a little degradation of the scaffolds was 
noted within 12 weeks. For this reason, in the future, further research will become necessary with 
longer experimental times for the in vivo studies. 
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It would be interesting to test other cell lines, used in tissue engineering, for the evaluation of 
scaffolds colonization, such as hMSC (human mesenchymal stromal cells) (Veronesi F, et al., 2011), 
and hADSC (primary human adipose derived stromal cells) (Levi B, et al., 2011), because of their 
ability to undergo osteogenic differentiation as well as hMSC, and the interest in these kinds of 
cells is greatly increasing in these last years (Salerno A, et al., 2010, Veronesi F, et al., 2011).  
The implantation of one single bone substitute has been associated with different success rates 
ranging between 50% and 90%: for this reason the idea of ‘‘polytherapy’’ is arising in the 
orthopaedic field and consists in the utilization and simultaneous implantation of all the three 
tissue engineering fundamental components MSCs, growth factors and scaffolds, even if, further 
investigations are needed  to optimize the harvesting, isolation, cultivation and preparation for 
clinical application (Arthur A, et al., 2009). Polytherapy therefore may be a logical option, 
especially in individuals of advanced age with associated co-morbidities and a limited capacity for 
tissue regeneration. In such cases, it could potentially accelerate fracture healing, facilitate early 
mobilization of patients, and reduce morbidity, health-care costs and complications associated 
with ongoing cases of impaired fracture healing. Based on experimental and clinical experiences, 
the application of a scaffold alone could be not enough for restoring large bone loss, particularly in 
complex non-unions in some patients. In order to improve decision making regarding which bone 
substitute has to be used to treat large defects properly, more standardized studies are necessary 
to better understand the use of the scaffolds.  
Materials with similar chemical and physical compositions do not necessarily possess the same 
structural, biological and biomechanical properties or follow the same resorption pathway or even 
result in the same healing characteristics. Therefore, proper assessment of the biological and 
mechanical environment and accurate patient selection are necessary. A sound understanding of 
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various aspects of scaffold properties and their relation and influence towards bone healing is of 
importance (Janicki P and Schmidmaier G, 2011). 
Further investigations on the scaffolds will be performed in terms of fabrication techniques and 
mechanical tests that will be refined to improve and better understand the quality of the scaffolds 
for orthopaedic applications.  
Thanks to the adopted methodology, a future collaboration between Preclinical and Surgical 
Studies laboratory and other departments or Universities will be proposed for the possibility to 
select the best composite scaffold with more relevant promising features, and new materials with 
different degradability, surface chemistry and porosity for bone regeneration.  
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